| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Illumina, Inc.$189.47
-4.62 (-2.38%)
C 53Pipeline Score Tools & Services · Commercial
Market Cap
21.85 B
EPS
5.54
P/E Ratio
26.21 $
Value Trade
530.83 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.09 B
R&D Expenses
240.00 M
Operating CF
289.00 M
Total Assets
6.56 B
Total Liabilities
6.56 B
Equity
2.68 B
D/E Ratio
12,345
2.09 %
Week
8.4 %
1 Month
24.3 %
3 Month
21.09 %
6 Month
-62.64 %
5 Year
894.78 %
All Time
Cash Data
Cash Position
1.09 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 4, 2026
Overview
Volume
1.74 M
52 Week Range
78.79 - 155.53
% held by Insiders
0.27 %
% held by Institutions
105.19 %
Enterprise Value
23.24 B
Total Shares
151.89 M
Short %
5.93 %
Float Shares
147.49 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Illumina, Inc.
334Total events
7Upcoming
80Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2Product Launch
Subscribe to view catalyst details
Event history 2
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
TBD
▲Enrollment MilestoneTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
C53
Pipeline Score $1.6B
Pipeline ValueValuation Signal
3
Drugs Scored0.2x
rNPV / MCap Top 82%
Mid Cap (rank 165 of 913)
Percentile RankIllumina, Inc. carries a moderate pipeline score (53/100), with $1.8B risk-adjusted pipeline value, led by 18F-MFBG in Neuroblastoma (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18F-MFBG Small molecule | Neuroblastoma | Phase 3 | NCT04724369 | 46% | $980M | ACTIVE NOT_RECRUITING | 43 | STALLED | D (27) | Aug 30, 2026 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Illuminare-1 (rizedisben) | Breast Reconstruction | Phase 1 | 2026-07-14 | 3.0 mg/kg; safety; favorable pharmacokinetics; clinical evidence of improved nerve visualization Read More | Illuminare Biotechnologies Appoints Veteran Biopharmaceutical Leader as New CEO Read More | |
Illuminare-1 (rizedisben) | Breast Reconstruction | Phase 1 | 2026-07-14 | 3.0 mg/kg; safety; favorable pharmacokinetics; clinical evidence of improved nerve visualization Read More | Illuminare Biotechnologies Appoints Veteran Biopharmaceutical Leader as New CEO Read More | |
Illuminare-1 (rizedisben) | Breast Reconstruction | Phase 1 | 2026-07-14 | 3.0 mg/kg; safety; favorable pharmacokinetics; clinical evidence of improved nerve visualization Read More | Illuminare Biotechnologies Appoints Veteran Biopharmaceutical Leader as New CEO Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ILMN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ILMN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ILMNIllumina expands Billion Cell Atlas program with new AI drug developers
Illumina has expanded its Billion Cell Atlas program by adding three new AI-driven drug developers, including Formation Bio. This collaboration aims to utilize Illumina's extensive genomic data to enhance drug discovery and development. The initiative is expected to help in identifying effective treatments and improving clinical trial designs, ultimately benefiting patient outcomes.
Read more →ILMNJuno Bio Opens First CLIA-Certified Sequencing Lab Dedicated Entirely to Women's Health, Backed by Ada Ventures, Artesian, Illumina Accelerator, and Entrepreneur First
Juno Bio has launched its first CLIA-certified sequencing lab focused on women's health, enhancing precision vaginal microbiome testing. The company secured $3.8 million in funding from notable investors to support this initiative. The lab aims to provide clinically actionable insights into vaginal health, addressing common but often misunderstood conditions. This development is expected to significantly improve care for women facing recurrent health issues.
Read more →ILMNElement Biosciences gewinnt deutschen Patentstreit gegen Illumina
Element Biosciences has won a patent dispute against Illumina in Germany. The Munich I District Court ruled that Illumina infringed on Element's patent related to imaging methods used in DNA sequencing. The ruling includes both direct and indirect infringement by Illumina, which could impact their operations in the region.
Read more →ILMNElement Biosciences Prevails in German Patent Case Against Illumina
Element Biosciences has secured a favorable ruling from the Regional Court of Munich I, determining that Illumina infringed on its patent rights related to an imaging method for DNA sequencing. The court found both direct and indirect infringement by Illumina, which may impact their operations in Germany. This ruling strengthens Element's position in the competitive biopharma landscape.
Read more →ILMNIlluminare Biotechnologies Appoints Veteran Biopharmaceutical Leader as New CEO
Illuminare Biotechnologies has appointed Brian Longstreet as CEO, effective June 1, 2026. His extensive experience in the biopharmaceutical sector is expected to guide the company through its Phase 2/3 development and commercialization. The company is set to initiate a Phase 2 trial for its product, Illuminare-1, following positive Phase 1 results.
Read more →ILMNIllumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
Illumina, Inc. will release its second quarter 2026 financial results on July 30, 2026. Following the announcement, CEO Jacob Thaysen and CFO Ankur Dhingra will host a conference call to discuss the results. Interested parties can access the call via Illumina's website, with a replay available for 30 days post-event.
Read more →ILMNIllumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
Illumina has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, effective July 20 and August 3, 2026, respectively. These appointments are aimed at strengthening the company's leadership as it continues to advance its strategy in genomics and human health. Sullivan brings extensive experience in commercial leadership, while Coletti has a strong background in legal and regulatory affairs.
Read more →ILMNBifrost Biosystems Pens Agreement with Illumina for Supply of Sequencing Chemistry for Optical Pooled Screening Platform
Bifrost Biosystems has entered into a commercial supply agreement with Illumina to incorporate Illumina's sequencing-by-synthesis chemistry into its optical pooled screening platform. This collaboration aims to enhance the platform's capabilities, which will be available for commercial use in early 2027. The agreement ensures reliable access to essential sequencing technology for Bifrost.
Read more →ILMNDaniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
Illumina, Inc. has appointed Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Skovronsky, currently the Chief Scientific and Product Officer at Eli Lilly, brings significant experience in drug discovery and clinical development. His expertise is anticipated to bolster Illumina's capabilities in genomics and precision medicine.
Read more →ILMNIllumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
Illumina has launched the StrataMap Spatial Solution, enhancing spatial transcriptomics capabilities for researchers. This end-to-end solution allows for whole-transcriptome profiling with true single cell resolution, significantly improving the detection of unique genes. It aims to support advancements in developmental biology, neuroscience, and oncology by providing deeper insights into tissue structure and function.
Read more →ILMNIntegrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
Integrated DNA Technologies (IDT) has announced a collaboration with Illumina to enhance oncology research workflows. This partnership integrates IDT's library preparation with Illumina's DRAGEN secondary analysis platform, aiming to streamline the process from sequencing to insights. The collaboration focuses on improving analysis for FFPE and cfDNA samples, ultimately supporting advancements in cancer research.
Read more →ILMN▲ +5.7%on this newsshared move
Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research Illumina, Inc. (NASDAQ: ILMN) today announced a new complete solution for molecular residual disease (MRD) research based on whole-genome sequencing...
Illumina, Inc. has announced the launch of a new whole-genome sequencing solution aimed at molecular residual disease (MRD) research. This distributed kit will allow laboratories to more effectively adopt MRD detection protocols for clinical research. Currently in early access for select partners, the solution offers high analytical sensitivity and quick turnaround times, making it suitable for detecting early-stage tumors. Early evaluations, including studies at the Mayo Clinic, indicate strong concordance with previous clinical results, suggesting promising potential for wider clinical application.
Read more →ILMN▲ +5.7%on this newsshared move
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
Illumina and SPT Labtech have launched the fireflyGO automation platform, designed to streamline targeted oncology research. This new solution integrates with the MiSeq i100 Series, enhancing workflow efficiency and accessibility in genomic testing. The platform aims to reduce manual processes and improve turnaround times for cancer testing, while expanding Illumina's oncology research portfolio.
Read more →ILMNDavid P. King elected to Illumina's Board of Directors Illumina, Inc. (NASDAQ: ILMN) today confirmed the election of David P. King to its Board of Directors, effective immediately following the company's...
Illumina, Inc. has announced the election of David P. King to its Board of Directors, effective immediately. King, the former Chairman and CEO of Labcorp, brings significant expertise in healthcare and diagnostics, which aligns with Illumina's goal of integrating genomics more deeply into standard healthcare practices. His leadership experience and knowledge in the industry is expected to bolster Illumina's clinical strategy and long-term impact on patients and shareholders. This change follows the retirement of three directors from the Board.
Read more →ILMNIllumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact
Illumina Inc. has released its 2025 Corporate Responsibility Report, showcasing its efforts to enhance access to genomics and its sustainability initiatives. The report highlights partnerships aimed at population-scale genomics and the company's achievements in reducing environmental impact. Illumina's commitment to community engagement and innovation in genomic technologies is also emphasized.
Read more →ILMN▲ +5.3%on this news· ran to +16% by day 3
Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 Illumina, Inc. (Nasdaq: ILMN) ( Illumina or the company ) today announced its financial results for the first quarter of fiscal year 2026. First...
Illumina, Inc. announced its financial results for Q1 2026, reporting a revenue of $1,091 million, an increase compared to Q1 2025. The company raised its guidance for full-year revenue and EPS, citing strong demand for its NovaSeq X product. Operating profit also saw a significant rise, accompanied by improved cash flow from operations. However, the company faces certain risks, including uncertainty tied to tariffs and integration challenges from recent acquisitions.
Read more →ILMNDRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.5 software (v4.5), one of the most substantial expansions of the...
Illumina has launched DRAGEN version 4.5, a software update that significantly enhances its genomic analysis capabilities. The new version includes improved variant calling accuracy, personalized features, and machine learning innovations aimed at tackling complex genomic regions. Researchers in oncology and rare disease studies are expected to benefit from these advancements, especially with regards to the detection of genetic and epigenetic markers. However, potential challenges in customer adoption and inherent product development risks remain.
Read more →ILMNIllumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease
Illumina has partnered with the Center for Data-Driven Discovery in Biomedicine to enhance research in pediatric cancer and rare diseases. This collaboration will utilize a large dataset of 100,000 whole genomes from pediatric patients, enabling real-time analysis and insights for improved patient care. The initiative aims to streamline data sharing across institutions, ultimately advancing precision medicine.
Read more →ILMNIllumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026
Illumina, Inc. will release its first quarter 2026 financial results on April 30, 2026. Following the announcement, CEO Jacob Thaysen and CFO Ankur Dhingra will host a conference call to discuss the results with analysts and investors. Interested parties can access the call via Illumina's website.
Read more →ILMNIllumina Announces Changes to Board of Directors
Illumina, Inc. announced significant changes to its Board of Directors, with Frances Arnold, Robert S. Epstein, and Gary S. Guthart set to retire. The company has nominated David P. King to join the Board, bringing valuable experience in healthcare and life sciences. This transition is aimed at fostering growth and innovation within the company.
Read more →ILMNDocument Illumina Announces Changes to Board of Directors David P. King nominated to support next phase of growth and innovation Frances Arnold, Robert S. Epstein, and Gary S. Guthart to retire from the Board
Illumina, Inc. has announced significant changes to its Board of Directors, nominating David P. King as a new member while three current members, Frances Arnold, Robert S. Epstein, and Gary S. Guthart, will retire during the upcoming annual meeting of shareholders. The company emphasizes that King's extensive healthcare and life sciences experience will support its next phase of growth and innovation. King has previously led complex organizations and has served in prominent roles within the industry. Illumina remains committed to advancing the integration of genomics in healthcare.
Read more →ILMNIllumina and Labcorp expand collaboration to broaden access to precision oncology testing
Illumina and Labcorp have announced an expanded collaboration to enhance precision oncology through next-generation sequencing solutions. The partnership aims to improve access to cancer biomarker testing and develop new tests to address unmet needs. They will also explore co-commercializing FDA-authorized liquid biopsy assays and continue joint efforts to demonstrate the clinical utility of comprehensive genomic profiling.
Read more →ILMNIllumina advances preventive genomics through strategic consortium with Veritas Genetics
Illumina has announced a strategic collaboration with Veritas Genetics to form a consortium focused on integrating preventive genomics into everyday healthcare. The initiative aims to utilize whole-genome sequencing for early disease risk detection and personalized prevention strategies. This partnership seeks to enhance research and clinical trial optimization while making genomic insights accessible to health insurance members.
Read more →ILMNAlliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering
Illumina and Nashville Biosciences have expanded the Alliance for Genomic Discovery by adding Regeneron Genetics Center as a member, increasing the dataset to 312,000 whole genomes. This expansion includes a new initiative to incorporate 50,000 whole genomes paired with proteomic data. The collaboration aims to enhance drug discovery and improve patient outcomes through advanced genomic and clinical data integration.
Read more →ILMN▲ +5.5%on this news
Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida
Illumina has partnered with the Florida Institute for Pediatric Rare Diseases to provide clinical whole-genome sequencing services, enhancing the diagnosis of rare diseases affecting millions of children. This collaboration aims to reduce the time from diagnosis to clinical management, offering hope for better treatment options. Illumina's technology is expected to significantly improve diagnostic accuracy and efficiency.
Read more →ILMNIllumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics
Illumina has announced significant advancements in cancer research through its multiomics solutions, including spatial transcriptomics and proteomics. These technologies are providing deeper insights into tumor biology and improving diagnostic accuracy for various cancers. Notable studies highlighted include the mapping of lymphatic systems and advancements in pediatric kidney cancer diagnostics, showcasing the potential for non-invasive testing methods.
Read more →ILMNIllumina launches TruPath Genome, setting a new standard in genomic insight
Illumina has launched TruPath Genome, a new technology that enhances whole genome sequencing with high accuracy and efficiency. This system can produce 16 genomes daily with minimal hands-on time and is designed to tackle complex genetic diseases. Priced at $395, it aims to provide comprehensive insights into genetic disorders, making it a valuable tool for researchers.
Read more →ILMNIllumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility
Illumina has announced an 18-month roadmap for the NovaSeq X system, featuring significant advancements in data quality, output, speed, and flexibility. Key updates include a 40% increase in output to 35 billion reads and the introduction of Q70 quality scores. These enhancements aim to improve sequencing productivity and support a wider range of applications, particularly in precision medicine and oncology.
Read more →ILMNIllumina To Webcast Upcoming Investor Conference Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming...
Illumina, Inc. announced its participation in an upcoming investor conference, marking another opportunity for management to engage with investors. The session will include a fireside chat scheduled for 12:10 PM PT, which will be available for live access and archived for later viewing. The company's ongoing focus on innovation in DNA sequencing aligns with their mission to improve human health. Illumina serves various sectors including life sciences, clinical markets, and oncology, reinforcing their prominent market position.
Read more →ILMN▼ -10.4%on this news
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025USA - English
Illumina, Inc. reported its financial results for Q4 and fiscal year 2025, highlighting a strong finish with a return to growth driven by increased adoption of next-generation sequencing (NGS) testing. The company reported a cash flow of $321 million for Q4 and $1.1 billion for the fiscal year. Despite positive results, Illumina faces uncertainties related to regulatory issues and market conditions as it moves into 2026.
Read more →ILMNIllumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally
Illumina has partnered with the San Diego Zoo Wildlife Alliance to sequence up to 4,000 samples from the Frozen Zoo®, a biobank of endangered species. This collaboration aims to leverage genomic insights to address conservation challenges and enhance biodiversity preservation. The initiative will utilize multiomic technologies to unlock vital information for wildlife medicine and ecological resilience.
Read more →ILMNIllumina completes acquisition of SomaLogic
Illumina has completed its acquisition of SomaLogic, enhancing its capabilities in proteomics and multiomics. This strategic move aims to provide scalable insights for drug discovery and improve healthcare outcomes. The integration of SomaLogic's technology with Illumina's existing platforms is expected to strengthen their market position. Financial details include a $350 million cash payment and potential performance-based milestones.
Read more →ILMNDocument Illumina completes acquisition of SomaLogic Deeply expands leadership in proteomics and multiomics Combined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination l
Illumina has successfully completed the acquisition of SomaLogic, augmenting its capabilities in proteomics and multiomics. This acquisition aims to enhance customer access to advanced proteomic insights, thereby improving drug discovery and patient outcomes. The integration of SomaLogic's technology with Illumina's existing platforms is expected to create scalable solutions for data analysis. However, Illumina faces challenges in successfully integrating the new business and technologies while managing customer relationships in the expanding proteomics market.
Read more →ILMNIllumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology
Illumina has secured reimbursement from CMS for its TruSight Oncology Comprehensive test, which is priced at $2,989.55. This decision is expected to enhance the adoption of comprehensive genomic profiling in oncology, allowing more healthcare providers to utilize precision oncology insights. The test assesses over 500 genes to inform treatment decisions and is crucial for identifying actionable biomarkers.
Read more →ILMNIllumina introduces Billion Cell Atlas to accelerate AI and drug discovery
Illumina has launched the Billion Cell Atlas, the largest genome-wide genetic dataset aimed at accelerating drug discovery through AI. In collaboration with AstraZeneca, Merck, and Eli Lilly, this initiative will create a comprehensive map of human disease biology. The Atlas will help validate drug targets and enhance understanding of complex diseases using advanced AI models.
Read more →ILMNIllumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025
Illumina, Inc. has announced its preliminary unaudited financial results for the fourth quarter and fiscal year 2025. The company will present these results at the 44th Annual J.P. Morgan Healthcare Conference. Full results are expected to be reported on February 5, 2026, and are subject to adjustments pending audits.
Read more →ILMNDocument Investors Conor McNamara +1.858.291.6421 ir illumina.com Media Christine Douglass pr illumina.com Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 San Diego
Illumina, Inc. has announced its preliminary unaudited financial results for the fourth quarter and fiscal year 2025. The company reported a revenue increase of approximately 5% in Q4 2025 compared to the same quarter of the previous year, driven by a substantial uplift in ex-China revenue. While the overall revenue for fiscal year 2025 was flat, the company anticipates full results to be reported on February 5, 2026. Management notes that these preliminary results are subject to further adjustments as accounting audits are completed.
Read more →ILMNIllumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026 Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2025 following the close of market on...
Illumina, Inc. (NASDAQ: ILMN) announced that it will disclose its financial results for the fourth quarter and full year 2025 on February 5, 2026. A conference call will be held the same day, featuring CEO Jacob Thaysen and CFO Ankur Dhingra, to review the financial and operating performance. Investors and analysts can access the live webcast through Illumina's website, with a replay available for 30 days post-event. The company's focus on innovation continues to position it as a leader in the DNA sequencing sector.
Read more →ILMNIllumina Appoints Dr. Eric Green as Chief Medical Officer Today, Illumina, Inc. (NASDAQ: ILMN) announced the appointment of Eric D. Green, M.D., Ph.D., as Chief Medical Officer (CMO), effective February 2....
Illumina, Inc. has appointed Dr. Eric Green as Chief Medical Officer, effective February 2, enhancing its executive leadership with his extensive experience in genomics. Dr. Green, known for his pivotal role at the National Human Genome Research Institute, is expected to drive Illumina's global medical strategy and further integrate genomics into clinical care. The announcement follows the departure of the chief commercial officer, Everett Cunningham, who has taken on a CEO role in another company. Jacob Thaysen, Illumina's CEO, will step in as interim chief commercial officer until a permanent successor is found.
Read more →ILMNDocument Illumina Appoints Dr. Eric Green as Chief Medical Officer Veteran genomics leader joins Illumina to advance global medical strategy Illumina chief commercial officer to depart for role as a life science tools co
Illumina, Inc. has appointed Dr. Eric Green as Chief Medical Officer, effective February 2, 2026. Dr. Green, a veteran in the field of genomics, will play a crucial role in advancing Illumina’s medical strategy and expanding access to precision medicine. His expertise will support the company’s mission to unlock the power of the genome for better health outcomes. Additionally, the company announced the departure of its chief commercial officer, Everett Cunningham, who will assume a CEO role at a life science tools company.
Read more →ILMNIllumina launches powerful software for connected, intuitive, and scalable multiomic analysis Illumina, Inc. (NASDAQ: ILMN) today announced the release of Illumina Connected Multiomics, a powerful cloud-based research software platform to...
Illumina, Inc. has launched the Connected Multiomics software platform, designed to facilitate multiomic analysis through AI-driven analytics and user-friendly workflows. This cloud-based solution aggregates thousands of multiomic samples and simplifies the analysis process, making it accessible to researchers without extensive bioinformatics backgrounds. Early feedback from users, such as the University of Colorado Anschutz Medical School, highlights its effectiveness in delivering biological insights. However, there are inherent risks associated with product development and customer acceptance.
Read more →ILMNIllumina To Webcast Upcoming Investor Conference
Illumina, Inc. has announced that its management team will participate in an upcoming investor conference. The presentation is scheduled for 7:30 a.m. PT, followed by a Q&A session. Investors can access the webcast through Illumina's website, with a replay available for 30 days post-event.
Read more →ILMNIllumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study
A new study published in Nature highlights the effectiveness of Illumina's whole-genome sequencing (WGS) in capturing genetic signals related to complex diseases. The research demonstrates that WGS can explain most of the 'missing heritability' in various traits, outperforming traditional methods like whole-exome sequencing. This advancement offers significant potential for drug discovery and precision healthcare.
Read more →ILMNIllumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks
Illumina's Protein Prep has launched globally, processing over 40,000 samples and providing extensive proteomic insights for more than 40 customers. It enhances genomic studies by integrating proteomics, facilitating significant advancements in disease research. Collaborations with institutions like Genomics England demonstrate its potential to improve disease classification and therapeutic target identification.
Read more →ILMNIllumina Responds to Positive Updates from Chinese Ministry of Commerce
Illumina, Inc. announced that the Chinese Ministry of Commerce will lift the export ban imposed on the company since March 2025. The ban will officially end on November 10, although Illumina remains on the Unreliable Entities List, requiring government approval for purchases. CEO Jacob Thaysen expressed optimism about the announcement and the company's commitment to resolving its status in China.
Read more →ILMN▲ +24.8%on this newsshared move
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025
Illumina, Inc. reported its financial results for Q3 2025, showing revenues of $1.084 billion, slightly up from the previous year. The company exceeded its revenue and earnings guidance, primarily driven by growth in its clinical segment. However, operating profit saw a significant decline compared to the previous year, raising concerns about rising expenses and legal contingencies. The company also provided a cautious outlook regarding future financial measures due to uncertainties.
Read more →ILMNIllumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights
Illumina has launched its 5-base solution, which allows simultaneous genomic and epigenomic analysis from a single sample. This advancement aims to enhance precision medicine by providing deeper insights into disease mechanisms and biomarker discovery. Early access customers, including researchers from the London Health Sciences Center, are already demonstrating its potential in rare disease cases at the ASHG annual meeting.
Read more →ILMNIllumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
Illumina's constellation mapped read technology is being piloted by GeneDx to enhance genomic insights for rare diseases. The technology has outperformed traditional methods in identifying difficult-to-map variants, showcasing its potential for rapid and accurate genomic analysis. GeneDx's Director will present findings at the ASHG Annual Meeting, highlighting the technology's promise in precision medicine.
Read more →ILMNIllumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025
Illumina, Inc. will announce its third quarter 2025 financial results on October 30, 2025. A conference call will be held at 1:30 pm PT to discuss these results with analysts and investors. The call will be accessible via Illumina's website, and a replay will be available for 30 days post-event.
Read more →ILMN▲ +7.7%on this news
Illumina launches new business to accelerate technology and data-driven discovery Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper...
Illumina, Inc. has launched BioInsight, a new business designed to provide advanced data assets, software, and AI solutions to enhance drug discovery and development. This initiative seeks to leverage the enormous potential of multiomic data in collaboration with pharmaceutical companies, enabling deeper biological insights. BioInsight aims to facilitate the generation and analysis of vast datasets, thereby accelerating the research and discovery process in life sciences. Rami Mehio will lead the new division, which is expected to reinforce Illumina's standing in the biotechnology sector.
Read more →ILMNIllumina advances personalized cancer care with new pharma development partnerships
Illumina has announced partnerships with multiple pharmaceutical companies to develop companion diagnostics focused on the KRAS biomarker, which is crucial for identifying patients who may benefit from targeted cancer therapies. This initiative aims to enhance access to precision oncology care by generating standardized tests. The advancements in genomic profiling will aid clinicians in matching patients to appropriate therapies based on genetic mutations.
Read more →ILMNAlnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (Alnylam) as a...
Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery, which aims to leverage a dataset of 250,000 whole genomes and an additional 31,250 genomes to enhance drug target discovery in precision medicine. The alliance focuses on using AI-powered datasets to drive innovative research in pharmacogenomics. Alnylam's participation will strengthen data diversity, enabling more effective therapeutic developments for patients from various backgrounds. This collaboration marks a significant enhancement in genomic research capabilities, with implications for novel treatment developments in complex diseases.
Read more →ILMNLancement d'Illumina® Protein Prep pour améliorer les connaissances protéomiques et faciliter les découvertes et le développement de médicaments Illumina Inc. (NASDAQ : ILMN) a annoncé aujourd'hui le lancement d'Illumina Protein Prep, un essai offrant des performances supérieures en matière de ...
Illumina Inc. has launched Illumina Protein Prep, a proteomics assay designed to enhance understanding of protein biology and support drug discovery. This assay, which offers superior performance by enabling the measurement of 9,500 unique protein targets, is available globally following a successful early access program. The technology integrates with Illumina's sequencing platforms to optimize proteomic studies, potentially aiding in the understanding of cancer and other diseases. Client feedback has been positive, highlighting the ease of use and effectiveness of the workflow.
Read more →ILMNIllumina® Protein Prep bringt neue Erkenntnisse aus der Proteomik für eine verbesserte Arzneimittelforschung und -entwicklung Illumina Inc. (NASDAQ: ILMN) hat heute die Einführung von Illumina Protein Prep bekannt gegeben, einem Assay, der überlegene Leistung für die...
Illumina Inc. has launched Illumina Protein Prep, an assay designed for large-scale proteomics research based on Next-Generation Sequencing (NGS). This innovative solution enables researchers to measure 9,500 unique human protein targets, offering extensive insights into protein biology and supporting the discovery of new treatment options for diseases. Following a successful Early Access Program, customers have highlighted its scalability, accuracy, and ease of use. The product intends to accelerate drug research and enhance the understanding of complex diseases.
Read more →ILMNIllumina® Protein Prep, daha iyi ilaç keşfi ve geliştirilmesi için daha fazla proteomik içgörü sağlamak üzere piyasaya sürüldü Illumina Inc. (NASDAQ: ILMN) bugün, yeni nesil sekanslama (NGS) tabanlı proteomik keşiflerinde üstün performans sunan Illumina Protein Prep testinin...
Illumina Inc. has launched the Illumina Protein Prep test, designed to provide superior performance in next-generation sequencing-based proteomic discoveries. The test, which can measure up to 9500 unique human protein targets, is aimed at inspiring new insights for disease treatments. Following the early access program, customer feedback highlighted its high consistency and ease of sampling. This launch also coincides with Illumina's recent acquisition of SomaLogic, further enhancing its capabilities in the proteomics field.
Read more →ILMNIllumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development Illumina Inc. (NASDAQ: ILMN) today announced the launch of Illumina Protein Prep, an assay introducing superior performance for next-generation...
Illumina Inc. has launched Illumina Protein Prep, a next-generation assay that significantly enhances proteomic analysis by enabling the measurement of 9500 unique human protein targets. This innovative tool aims to improve drug discovery and clinical research by providing faster and more accurate insights into protein biology. The company's early access program has garnered positive feedback from users about its scalability and efficiency, underscoring its potential in advancing proteogenomics. Additionally, Illumina plans to continue supporting the acquisition of SomaLogic, further enhancing its capabilities in the proteomics market.
Read more →ILMNSe lanza Illumina® Protein Prep para impulsar mayores conocimientos proteómicos -Se lanza Illumina® Protein Prep para impulsar mayores conocimientos proteómicos y mejorar el descubrimiento y desarrollo de fármacos Illumina...
Illumina Inc. has announced the launch of Illumina Protein Prep, a next-generation sequencing assay designed to enhance large-scale proteomics research. With the ability to measure 9500 unique human protein targets, this tool aims to improve biomarker discovery and drug development, particularly in the context of genomic studies related to cancer and metabolic diseases. Early feedback from customers indicates strong satisfaction with its performance and workflow integration. This launch is part of Illumina's broader strategy to advance multi-omics research and support global health initiatives.
Read more →ILMNIllumina Reports Financial Results for Second Quarter of Fiscal Year 2025 Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basis GAAP operating margin of 20.2% and non-GAAP ...
Illumina, Inc. reported its financial results for Q2 2025, showing a revenue of $1.06 billion, which is a 3% decline from the previous year. Despite this decrease, the company exceeded its guidance, attributed to growth in clinical segments and improved operational efficiency. The operating margin fell to 20.2%, significantly reduced from 40.5% due to impairment charges on intangible assets. The firm remains optimistic about increasing expectations for the year ahead, focusing on navigating challenges in the funding environment.
Read more →ILMNIllumina enhances flagship assay to accelerate access to comprehensive tumor profiling Illumina Inc. (NASDAQ: ILMN) today announced the launch of the next generation of TruSight Oncology 500, its flagship cancer research assay that...
Illumina has launched the upgraded TruSight Oncology 500 v2 assay, enhancing its cancer research capabilities with built-in homologous recombination deficiency (HRD) detection. The new version promises faster turnaround times and reduced tissue sample input requirements, broadening access to comprehensive tumor profiling. This upgrade aims to aid cancer therapy selection and improve patient outcomes through more efficient workflows. Early-access users have reported improved accuracy and minimized service costs with this latest offering.
Read more →ILMNIllumina named to TIME's World's Most Sustainable Companies list for the second consecutive year Illumina Inc. (NASDAQ: ILMN) today announced two awards recognizing the company's leadership in sustainability practices and as an employer of choice....
Illumina Inc. has been awarded recognition for its leadership in sustainability and employee experience, appearing on TIME's World's Most Sustainable Companies list for the second consecutive year. The company ranked second in the U.S. and third in the global Pharmaceuticals & Biotechnology Industry. Additionally, it was listed among the Best Companies to Work For by U.S. News & World Report. Illumina's commitment to sustainability is evident through significant reductions in packaging and complete reliance on renewable energy for its operations.
Read more →ILMNIllumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025 Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July...
Illumina, Inc. has announced an upcoming release of its second quarter 2025 financial results set for July 31, 2025. Following the release, the CEO and CFO will host a conference call to discuss the results with analysts and investors. The call will be accessible through a live webcast on the company's website, ensuring a direct line of communication with stakeholders. Illumina continues to assert its leadership in DNA sequencing and array-based technologies.
Read more →ILMNIllumina द्वारा SomaLogic का अधिग्रहण किया जाएगा, जिससे उसके प्रोटिओमिक्स बिज़नेस में तेजी आएगी और कंपनी की मल्टीओमिक्स रणनीति आगे बढ़ेगी Illumina, Inc. (NASDAQ: ILMN) ने घोषणा की है कि उसने Standard BioTools (NASDAQ: LAB) जिसके तहत Illumina द्वारा डेटा-संचालित प्रोटिओमिक्स टेक्नोलॉजी...
Illumina, Inc. has announced its acquisition of SomaLogic, a company specializing in proteomics technology. This strategic move is expected to enhance Illumina's capabilities in the growing field of proteomics, allowing for improved healthcare solutions. The acquisition is projected to significantly impact the market, with a focus on innovation and expansion in proteomics applications.
Read more →ILMNIllumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy Illumina, Inc. (NASDAQ: ILMN) announced it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will...
Illumina has announced its acquisition of SomaLogic for $350 million, aimed at enhancing its capabilities in the expanding proteomics market. This strategic move is expected to bolster Illumina's multiomics strategy and improve its product offerings, particularly the NovaSeq X. The transaction is set to close in the first half of 2026, pending regulatory approval.
Read more →ILMNイルミナ、SomaLogicを買収 プロテオミクス事業を強化し、マルチオミクス戦略を加速 ゲノム解析およびシーケンシングの分野で世界をリードするIllumina, Inc.（NASDAQ: ILMN）は、データ駆動型プロテオミクス技術のリーディングカンパニーであるSomaLogic社とその他の資産を買収するため、Standard...
Illumina, Inc. (NASDAQ: ILMN) has announced its acquisition of SomaLogic, a leader in proteomics technology, to enhance its product portfolio. The acquisition is expected to accelerate growth in the proteomics market, leveraging SomaLogic's advanced capabilities. This strategic move aims to strengthen Illumina's position in health and agricultural applications.
Read more →ILMNIllumina to acquire SomaLogic, accelerating its proteomics business and advancing the company s multiomics strategy Combines highly complementary proteomics expertise with Illumina s industry-leading product innovation a
Illumina, Inc. has announced its intention to acquire SomaLogic for $350 million in cash, along with performance-based milestones. This acquisition aims to enhance Illumina's position in the expanding proteomics market and to advance its multiomics strategy. The deal combines SomaLogic's data-driven proteomics technology with Illumina's next-generation sequencing capabilities, allowing for improved biomarker discovery. Expected to close in the first half of 2026, the integration may face regulatory and operational challenges.
Read more →ILMNIllumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina...
Illumina has announced its acquisition of SomaLogic for $350 million, aimed at enhancing its presence in the growing proteomics market. This acquisition will support Illumina's multiomics strategy and improve its product offerings, particularly the NovaSeq X. The deal is expected to close in the first half of 2026, pending regulatory approvals.
Read more →ILMNlllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social...
Illumina Inc. has released its 2024 Corporate Social Responsibility (CSR) report, highlighting its commitment to advancing health equity through genomics. CEO Jacob Thaysen mentioned that while innovation has led to significant breakthroughs, access to these advancements is crucial. The report showcases progress in four key areas of the company's CSR strategy, aimed at benefiting patients, communities, employees, and the environment. Illumina continues to position itself as a leader in DNA sequencing and array-based technologies.
Read more →ILMNIllumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the...
Illumina has launched PromoterAI, a new AI algorithm designed to identify pathogenic regulatory genetic variants in the noncoding regions of the human genome. This innovative technology aims to enhance the diagnosis of rare diseases, which currently see only a 30% accurate diagnosis rate through exome sequencing. PromoterAI interprets genetic sequences in regulatory promoter regions, which are crucial for gene expression. This release follows Illumina's previous AI advancements and is expected to significantly accelerate breakthroughs in genetic diagnosis for rare diseases.
Read more →ILMNIllumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies Illumina Inc. (NASDAQ: ILMN) today announced an expanded clinical oncology portfolio, unlocking the next new solutions to advance precision oncology...
Illumina Inc. (NASDAQ: ILMN) has announced an expansion of its clinical oncology portfolio, which includes broader access to its TSO Comprehensive genomic profiling test. This test has received widespread reimbursement coverage and is now being utilized in various healthcare settings across the U.S. Additionally, Illumina has partnered with Pillar Biosciences to introduce the oncoReveal CDx, aimed at enhancing genetic diagnostics for patients with solid tumors. The TSO Comprehensive test is also recognized as the first FDA-approved kit for comprehensive genomic profiling, which evaluates both DNA and RNA.
Read more →ILMNIllumina To Webcast Upcoming Investor Conference Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 41st Annual Bernstein...
Illumina, Inc. (NASDAQ: ILMN) has announced that its executives will present at the upcoming 41st Annual Bernstein Investor Conference. The event will be webcasted and accessible on Illumina's Investor Info section of their website, with a replay available for at least 30 days post-event. This initiative underscores Illumina's commitment to stakeholder engagement and innovation in the genomics field.
Read more →ILMNIllumina DRAGEN v4.4 powers clinical oncology research and multiomic applications Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.4 software (v4.4), the industry's most comprehensive secondary analysis...
Illumina Inc. has launched DRAGEN version 4.4 software, enhancing its secondary analysis capabilities for clinical oncology and multiomics applications. The new version features a 30% improvement in accuracy for germline structural variant calling and includes several out-of-the-box applications designed to simplify the analysis process. The University Hospital of Tübingen in Germany is among the first to adopt this software for a pioneering study focused on evaluating its clinical utility. This initiative aims to further understand the insights generated from whole-genome germline testing.
Read more →ILMNIllumina Reports Financial Results for First Quarter of Fiscal Year 2025 Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin of 15.8% and...
Illumina, Inc. reported its financial results for the first quarter of fiscal year 2025, revealing a core revenue of $1.04 billion, a slight decrease from the previous year's $1.056 billion. While net income improved significantly to $131 million, the company expressed concerns over a weakened outlook due to geopolitical factors. Operating margins took a hit, falling to 15.8%, compared to 20.4% a year prior. Illumina remains committed to strategic innovations and customer collaborations to navigate this challenging business environment.
Read more →ILMNIllumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development Illumina, Inc. (NASDAQ: ILMN), and Ovation.io, Inc., an organization dedicated to building best-in-class multiomics datasets, today announced the...
Illumina, Inc. and Ovation.io, Inc. have announced the development of an extensive multiomic dataset derived from 25,000 patients treated with GLP-1 receptor agonists. This initiative aims to advance research on GLP-1 therapies, particularly for patients who do not respond effectively to current treatments. By integrating genomic and proteomic data, the dataset is expected to reveal new drug targets and improve therapy indications. This collaboration marks a significant step in understanding metabolic diseases and enhancing therapies for diabetes and obesity.
Read more →ILMNIllumina and Tempus partner to drive the future of precision medicine through genomic AI innovation Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and...
Illumina and Tempus have announced a partnership aimed at advancing precision medicine through genomic AI innovation. This collaboration builds on their previous work to develop tools for molecular profiling, addressing testing needs from screening to therapy selection. Both companies underscore the importance of overcoming challenges related to product development and market acceptance while highlighting their focus on improving patient outcomes. Despite this optimistic outlook, they acknowledge significant risks tied to product launches and supply chain dependencies.
Read more →ILMN▼ -6.6%on this newsshared move
Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025 Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8,...
Illumina, Inc. has announced it will release its first quarter 2025 financial results on May 8, 2025. The company's CEO, Jacob Thaysen, and CFO, Ankur Dhingra, will host a conference call to discuss the results with analysts and investors. Interested parties can access the call via Illumina's website, with a replay available for 30 days afterwards. This announcement reflects Illumina's continued commitment to providing updates on its financial performance to stakeholders.
Read more →ILMNIllumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors....
Illumina, Inc. has announced significant changes to its Board of Directors, electing Dr. Scott Gottlieb as non-executive Chair while welcoming Keith Meister as a new board member. Stephen MacMillan will retire from the board in preparation for the upcoming annual shareholders' meeting. Dr. Gottlieb and Mr. Meister bring extensive expertise and a commitment to advancing the company's strategic goals, particularly in the field of genomics. This transition aims to strengthen Illumina's leadership and drive continued innovation and growth in genomics applications for healthcare.
Read more →ILMNDocument Illumina Board of Directors Elects Dr. Scott Gottlieb Chair, Keith Meister to Join Board of Directors Stephen MacMillan to retire from the Board
Illumina, Inc. has announced significant changes to its Board of Directors, with Dr. Scott Gottlieb elected as the new non-executive Chair. Keith Meister is set to join the board on March 28, 2025, while Stephen MacMillan will retire before the annual shareholder meeting. Dr. Gottlieb emphasized the company's transformative role in genomics, and both he and Mr. Meister expressed confidence in Illumina's growth and innovation trajectory.
Read more →ILMNAlliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of...
Illumina and Nashville Biosciences have sequenced 250,000 whole genomes as part of the Alliance for Genomic Discovery (AGD), creating a significant clinical genomic dataset. This resource is being utilized to enhance drug discovery and therapeutic research, leveraging insights from diverse genomic data. The initiative is set to expand further by incorporating multiomic measurements, aiming to provide deeper biological insights and accelerate the development of therapeutics. The rapid achievement showcases the potential of collaborative efforts in genetic research.
Read more →ILMNDocument Investors Salli Schwartz +1.858.291.6421 ir illumina.com Media Bonny Fowler +1.740.641.5579 pr illumina.com Illumina addresses recent developments in China Announces Fiscal Year 2025 Non-GAAP Diluted EPS of Appr
Illumina (ILMN) is addressing a recent restriction from China's Ministry of Commerce that prohibits the export of its sequencing instruments to the country. Despite this setback, the company maintains a targeted non-GAAP diluted EPS of approximately $4.50 for FY 2025, and is focusing on high-single-digit revenue growth by 2027. In response to potential revenue impacts from China, Illumina is initiating a cost reduction program of approximately $100 million. The company aims to remain competitive through innovation in its multiomics portfolio and other technological advancements.
Read more →ILMNIllumina addresses recent developments in China Illumina, Inc. (Nasdaq: ILMN) ( Illumina or the company ) today responded to the March 4, 2025 notice from the China Ministry of Commerce...
Illumina, Inc. addressed its ongoing strategies and fiscal expectations for 2025, announcing a projected non-GAAP diluted EPS of approximately $4.50. The company is strategically focusing on multiomics expansion and cost reduction initiatives amidst anticipated challenges in the Greater China market. CEO Jacob Thaysen expressed confidence in the long-term growth opportunities within genomics, highlighting investments in new technologies to support researchers. Nevertheless, the firm is cautious about the financial contribution from China, which is included in their cost-saving measures moving forward.
Read more →ILMNIllumina named to Dow Jones Best-in-Class Indices for sixth consecutive year and as a Sustainability Yearbook Member for fourth consecutive year Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, has been named for the sixth year in a row to the Dow...
Illumina, Inc. has been recognized for the sixth consecutive year in the Dow Jones Best-in-Class World and North America Indices, marking a significant achievement in sustainability practices among companies. This recognition highlights Illumina's commitment to innovative and sustainable business practices, including the launch of products that reduce packaging waste and utilize recyclable materials. Additionally, Illumina has maintained 100% renewable energy usage for its operations for three consecutive years. The company is set to release its Corporate Social Responsibility report later this year, detailing its environmental targets and progress.
Read more →ILMNIllumina transforms multiomic research with new technologies to unlock deeper understanding of biology Illumina, Inc. (NASDAQ: ILMN) has unveiled a series of roadmap innovations, establishing the industry's largest portfolio of omics solutions and...
Illumina, Inc. has introduced groundbreaking innovations in multiomics, establishing the largest portfolio in the industry with advancements in genomics, spatial transcriptomics, and CRISPR technology. These developments promise to enhance research capabilities and lead to improved disease understanding and diagnosis. Notably, the company is focusing on the creation of a multimodal data analysis platform to streamline workflows for researchers. Despite the promising outlook, Illumina acknowledges potential challenges in product development and customer acceptance in the competitive biopharma landscape.
Read more →ILMNIllumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad ...
Illumina, Inc. has announced a collaboration with Broad Clinical Labs to enhance drug discovery through single-cell solutions. This partnership aims to develop a 5 billion cell atlas within three years by integrating Illumina's sequencing technologies with Broad's advanced CRISPR Perturb-seq techniques. Together, they plan to support high-throughput processing of single-cell samples, facilitating large-scale functional genomics studies. However, the announcement includes acknowledgment of potential challenges in manufacturing and market acceptance of new products.
Read more →ILMNIllumina unveils first-of-its-kind spatial transcriptomics technology Illumina, Inc. (NASDAQ: ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and understand...
Illumina, Inc. has announced a groundbreaking spatial technology program aimed at enabling researchers to conduct high-resolution mapping of complex tissues. This new spatial transcriptomics technology will offer unprecedented capabilities for whole-transcriptome profiling and drives significant advancements in several fields, including cancer research and neurobiology. The company will also introduce a multimodal analysis platform, Illumina Connected Multiomics, designed to enhance data visualization and analysis. Furthermore, Illumina is collaborating with the Broad Institute on a Spatial Flagship Project to promote cooperation and innovation in spatial research.
Read more →ILMNIllumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming...
Illumina, Inc. (NASDAQ: ILMN) announced an upcoming investor session at the Advances in Genome Biology and Technology (AGBT) conference, scheduled for February 25, 2025. The session will include a fireside chat featuring CEO Jacob Thaysen, CFO Ankur Dhingra, and CTO Steve Barnard. Interested parties can access the live webcast via Illumina's website. A replay of the event will also be available online for at least 30 days after the session.
Read more →ILMNIllumina Reports Financial Results for Fourth Quarter and Fiscal Year 2024 Core Illumina revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023 on both a reported and constant currency basis; revenue of $4.3 billion for...
Illumina, Inc. reported its financial results for Q4 and fiscal year 2024, revealing a fourth-quarter revenue of $1.1 billion, a 1% increase from Q4 2023. The company emphasized its commitment to customer-focused innovation and operational excellence as part of their transformation strategy for 2025. However, despite achieving stronger revenue and margins, the overall revenue for fiscal year 2024 saw a slight decline compared to the previous year, and net income fell significantly year-over-year.
Read more →ILMN▼ -5.4%on this news
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and Provides Preliminary Outlook for Fiscal Year 2025 Illumina, Inc. (NASDAQ: ILMN) ( Illumina or the company ) today announced unaudited preliminary financial results for the fourth quarter and fiscal ...
Illumina, Inc. announced its preliminary unaudited financial results for Q4 and FY 2024, revealing revenue of $4,332 million, a slight decrease from the previous year. The company will present its full results on February 6, 2025, indicating an upcoming opportunity for investors to assess its performance. The preliminary outlook for FY 2025 was also provided but is subject to risks and uncertainties that could significantly impact actual outcomes. Notably, challenges and costs associated with product development and market dynamics were highlighted as potential risks.
Read more →ILMN▼ -5.4%on this news
Document Investors Salli Schwartz +1.858.291.6421 ir illumina.com Media Bonny Fowler +1.740.641.5579 pr illumina.com Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and
Illumina, Inc. announced its preliminary unaudited financial results for the fourth quarter and fiscal year 2024, revealing revenue of approximately $1.10 billion for Q4 2024, which marks a 1% increase from the previous year. Despite this positivity, the overall annual revenue for 2024 decreased by 2% compared to 2023. The company also provided a preliminary outlook for fiscal year 2025, indicating low single-digit revenue growth and a projected non-GAAP diluted EPS growth of around 10%. These results will be finalized and reported on February 6, 2025.
Read more →ILMN▲ +5.5%on this newsshared move
Illumina and NVIDIA collaborate to decode biology and propel precision health Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance...
Illumina, Inc. has announced a collaboration with NVIDIA to enhance the analysis and interpretation of multiomic data using AI technologies. This partnership aims to combine Illumina's genomic sequencing capabilities with NVIDIA's acceleration tools to boost drug discovery and clinical research. The collaboration will leverage existing advancements in AI to streamline genomic data analysis and improve the performance of tools for pharmaceutical companies. The first phase includes enabling Illumina's algorithms on NVIDIA GPUs, enhancing accessibility to multiomic analysis for the global R&D community.
Read more →ILMN▲ +5.5%on this newsshared move
Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze...
Illumina, Inc. has announced a pilot proteomics program in collaboration with the UK Biobank and several biopharma companies to analyze 50,000 samples. The initiative aims to utilize Illumina's Protein Prep solution, leveraging advanced technology to enhance the understanding of protein's roles in health and disease. As part of the program, the first 30,000 samples will be processed and made available to the scientific community, followed by additional data from the remaining samples. This project seeks to advance biomarker discovery and improve drug discovery efforts across various health conditions.
Read more →ILMNIllumina to Announce Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 6, 2025 Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2024 following the close of market on...
Illumina, Inc. announced it will release its fourth quarter and full year 2024 financial results after market close on February 6, 2025. A conference call will follow the release, featuring CEO Jacob Thaysen and CFO Ankur Dhingra to discuss the results. Interested participants can access the call via a webcast on the company's website. Illumina continues to innovate in genomic technologies, serving various markets related to health and life sciences.
Read more →ILMNIllumina advances NovaSeq X Series, delivering single-flow-cell system, software upgrade, and new kits to enable multiomic applications Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of updates to its NovaSeq X...
Illumina, Inc. has announced significant updates to its NovaSeq X Series, including the launch of a new single-flow-cell Sequencing System, a software upgrade (version 1.3), and new 25B assay kits. The single-flow-cell system aims to provide high-quality sequencing at a more affordable cost for smaller labs, while the software upgrade promises enhanced sequencing accuracy and improved data yield. The new kits are designed to facilitate multiomic applications, supporting the growing demands of clinical and research laboratories.
Read more →ILMNIllumina To Webcast Upcoming Investor Conference Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 43rd Annual J.P. Morgan...
Illumina, Inc. (NASDAQ: ILMN) announced its participation in the 43rd Annual J.P. Morgan investor conference. Executives from the company will speak at the event, which will be webcast for stakeholders. A replay will be available on Illumina's website for at least 30 days following the conference. The company is a leader in DNA sequencing and technology, serving various markets including life sciences and oncology.
Read more →ILMNIllumina announces expansion of TruSight Oncology portfolio Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release TruSight™...
Illumina, Inc. has announced the forthcoming release of TruSight Oncology 500 v2, a new version of its cancer research assay designed for comprehensive genomic profiling of tumors. The product will be revealed at the annual meeting of the Association of Molecular Pathology, with global availability anticipated by mid-2025. Enhancements include a faster workflow and improved sensitivity in detecting rare genetic biomarkers. The company emphasizes ongoing development to meet diverse customer needs within its oncology portfolio.
Read more →ILMNIllumina To Webcast Upcoming Investor Conferences Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: Wolfe Research 2024...
Illumina, Inc. (NASDAQ: ILMN) announced that its executives will be participating in various upcoming investor conferences. The webcasts will be accessible via the Investor Info section of Illumina's website, with replays available for 30 days post-event. The company continues to solidify its position as a leader in DNA sequencing and related technologies, emphasizing its commitment to innovation in improving human health.
Read more →ILMNIllumina Reports Financial Results for Third Quarter of Fiscal Year 2024 Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis Core Illumina GAAP operating margin of 68.6% ...
Illumina, Inc. has announced its financial results for Q3 2024, revealing a slight decline in Core Illumina revenue to $1.1 billion, a 2% drop from the previous year. The company highlighted strong operating results, with an operating margin of 68.6% and improvements in cash flow. However, Illumina is lowering its revenue guidance for the year amidst a constrained macroeconomic environment. Despite these challenges, the underlying demand for its products remains strong, and the company is making progress towards its strategic goals.
Read more →ILMNIllumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will present updates on...
Illumina, Inc. will present its latest innovations in DNA sequencing and multiomic technologies at the American Society of Human Genetics Annual Meeting in Denver. Highlights include the unveiling of its constellation mapped read technology designed to improve whole-genome sequencing and updates on the Illumina Protein Prep for proteomics. These innovations are aimed at enhancing genomic insights and allowing researchers to study over 6000 human proteins. However, the company acknowledges potential challenges in product development and market acceptance.
Read more →ILMNIllumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today unveiled its MiSeq™ i100 Series of sequencing...
Illumina has launched its MiSeq i100 Series of benchtop sequencers aimed at improving access to next-generation sequencing (NGS). These instruments offer features such as room-temperature storage, minimizing delays in sequencing projects, and increasing flexibility for labs. The MiSeq i100 Series promises to deliver faster results with enhanced ease of use, supported by positive early customer feedback. This new series continues to build upon Illumina's history of technological innovation in the genomic space.
Read more →ILMNIllumina to Announce Third Quarter 2024 Financial Results on Monday, November 4, 2024 Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2024 following the close of market on Monday, November ...
Illumina, Inc. announced it will release its third quarter 2024 financial results after the market closes on November 4, 2024. A conference call with CEO Jacob Thaysen and CFO Ankur Dhingra will follow to discuss these results with analysts and investors. Interested parties can listen to the call via Illumina's website or by phone, with a replay available for 30 days post-event. The company continues to lead in DNA sequencing and array-based technologies.
Read more →ILMNCharles Dadswell to step down as General Counsel, Illumina initiates search for successor Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that after 11 years of service, Charles...
Illumina, Inc. (NASDAQ: ILMN) announced that Charles Dadswell will step down as General Counsel and Secretary, effective October 3, 2024, after 11 years with the company. He will remain until March 31, 2025, acting as an advisor to the CEO and Board of Directors. Scott Davies has been named the acting General Counsel while a search for a permanent successor is initiated. Dadswell's tenure is noted for significant contributions to the company's legal challenges and growth in the biotechnology sector.
Read more →ILMNEuropean Court of Justice rules in favor of Illumina in jurisdictional appeal Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's)...
Illumina, Inc. welcomed a favorable ruling from the European Court of Justice, stating that the European Commission exceeded its jurisdiction concerning Illumina's acquisition of GRAIL. As a result, a previously imposed 432 million euro fine has been rescinded. The decision follows the successful spin-off of GRAIL, now an independent company, in June 2024. This ruling aligns with the recent dismissal of related cases by U.S. FTC Commissioners, allowing Illumina to continue its operations without significant regulatory setbacks.
Read more →ILMNFDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA)...
Illumina, Inc. has received FDA approval for its TruSight™ Oncology Comprehensive test, which analyzes over 500 genes to improve the identification of actionable biomarkers for solid tumors. This test includes companion diagnostics for patients with specific gene fusions, potentially benefiting from targeted therapies. The approval enables broader molecular profiling in advanced cancer management, facilitating better treatment decisions. Shipping of the TSO Comprehensive test is set to begin this year, aligning with reimbursement policies from Medicare and Medicaid services.
Read more →ILMNIllumina announces strategy to accelerate value creation -- Company poised to accelerate revenue growth into high single digits over next three years, enabled by core genomics portfolio -- Innovations to...
Illumina has announced a strategy update highlighting its plans to accelerate revenue growth to high single digits within three years, driven by innovations in its core genomics portfolio. The company will also deliver significant non-GAAP diluted earnings per share growth from 2025 to 2027. Additionally, Illumina has partnered with the Broad Institute to enhance single-cell sequencing capabilities. Despite these positive developments, the company acknowledged potential risks that could affect its growth targets and operational execution.
Read more →ILMNIllumina Reports Financial Results for Second Quarter of Fiscal Year 2024 Core Illumina revenue of $1.09 billion for Q2 2024, down 6% from Q2 2023 (down 6% on a constant currency basis) and up 3% from Q1 2024 Core Illumina...
Illumina, Inc. reported its financial results for the second quarter of fiscal year 2024, showing Core revenue of $1.09 billion, which is a 6% decrease from Q2 2023 and a 6% drop on a constant currency basis. The CEO, Jacob Thaysen, mentioned that while consumable sales remained strong, instrument demand has softened due to a constrained funding environment. The company recognized significant impairments related to its GRAIL segment, which contributed to an operating loss of $1.637 billion. For the fiscal year 2024, Illumina has lowered its revenue guidance while raising its operating margin projections.
Read more →ILMNIllumina launches new oncology menu for NovaSeq X Series customers Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has expanded its oncology menu for...
Illumina has expanded its oncology menu for NovaSeq X Series customers by introducing the high-throughput version of TruSight Oncology 500 and the new version of its liquid biopsy assay, TruSight Oncology 500 ctDNA v2. These advancements aim to improve genomic profiling of tissue and liquid biopsy samples, offering faster sequencing and economic benefits. The new assays will enhance the capabilities for oncology testing research, facilitating therapy selection based on comprehensive genomic data. There's also a plan to extend TSO 500 HT to the company's NextSeq Systems soon.
Read more →ILMNIllumina to Present Upcoming Strategy Update As Illumina, Inc. (NASDAQ: ILMN) previously announced on June 24, the company will present a Strategy Update on Tuesday, August 13, 2024 starting at...
Illumina, Inc. (NASDAQ: ILMN) has announced a Strategy Update event to take place on August 13, 2024. This event will include presentations from members of Illumina's executive team and will conclude with a Q&A session. Investors can access a webcast of the event through the company's Investor Relations website, and a replay will be available for 30 days post-event. The company continues to focus on innovation in genomic technologies, aiming to improve human health across various sectors.
Read more →ILMNIllumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 As Illumina, Inc. (NASDAQ:ILMN) previously announced on June 24, the company will issue results for the second quarter 2024 following the close of...
Illumina, Inc. (NASDAQ: ILMN) plans to announce its second quarter 2024 financial results on August 6, 2024. The announcement will be followed by a conference call led by CEO Jacob Thaysen and CFO Ankur Dhingra to discuss the results with analysts and investors. This event underscores Illumina's focus on maintaining communication with stakeholders and reinforces its leading position in the DNA sequencing industry.
Read more →ILMNIllumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that effective today it has acquired Fluent...
Illumina, Inc. has acquired Fluent BioSciences, enhancing its single-cell analysis capabilities in multiomics. This acquisition, effective July 9, 2024, allows Illumina to offer a more accessible and scalable approach to single-cell research, eliminating the need for complex instruments. Fluent's innovative PIPseq V technology will be integrated into Illumina's product portfolio, enabling customers to conduct advanced multiomic analysis more efficiently. The acquisition supports Illumina's commitment to providing comprehensive solutions while continuing to maintain existing partnerships in the single-cell market.
Read more →ILMNIllumina completes the divestiture of GRAIL GRAIL spin-off complete; GRAIL to begin regular way trading as GRAL on June 25 Illumina to issue second quarter 2024 results on August 6; leadership to present Strategy Update
Illumina, Inc. has successfully completed the spin-off of GRAIL, allowing it to begin trading on Nasdaq under the ticker symbol GRAL. Following the distribution of GRAIL shares to Illumina shareholders, GRAIL operates independently while Illumina retains a 14.5% stake. Illumina plans to issue its second quarter results on August 6, 2024, and discuss its strategic plans in a virtual update on August 13. This divestiture is expected to enhance both companies' focuses on innovation and customer needs, particularly in oncology.
Read more →ILMNIllumina completes the divestiture of GRAIL Illumina, Inc. (NASDAQ: ILMN) today announced the successful completion of the spin-off of GRAIL. This milestone follows the company's previously...
Illumina, Inc. has successfully completed the spin-off of GRAIL, which will commence trading as an independent entity on Nasdaq under the ticker symbol 'GRAL'. This move is part of Illumina's strategy to focus on its core business while still maintaining a 14.5% stake in GRAIL. The spin-off is aimed at allowing GRAIL's advancements in cancer technology to flourish independently. Illumina plans to provide ongoing support through its sequencing technology and services.
Read more →ILMNIllumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of DRAGEN™ v4.3, the latest...
Illumina has launched DRAGEN v4.3, which features innovative updates aimed at enhancing genome analysis. This version includes multigenome mapping technology and built-in mosaic calling, improving accuracy and efficiency for researchers. In collaboration with the Human Pangenome Reference Consortium, DRAGEN v4.3 allows users to select from a variety of ancestries for genomic mapping, increasing the tool's applicability. However, there are potential risks associated with product development and market acceptance.
Read more →ILMNIllumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it has completed integration of its...
Illumina Inc. has announced the integration of its XLEAP-SBS chemistry into the NextSeq 1000 and 2000 sequencing systems, promising improved speed, quality, and cost-efficiency. Early-access customers have reported positive experiences regarding the quality and stability of sequencing runs. The company aims to enhance the capacity for larger genomic projects without increased costs, particularly encouraging the use of multiomic techniques. Despite these advancements, the company acknowledges potential challenges and uncertainties that may affect product acceptance and performance outcomes.
Read more →ILMNIllumina appoints Everett Cunningham Chief Commercial Officer Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment of Everett Cunningham...
Illumina, Inc. has appointed Everett Cunningham as Chief Commercial Officer, effective June 10, 2024. He brings over 20 years of commercial leadership experience from roles at Exact Sciences, Quest Diagnostics, GE Healthcare, and Pfizer. Cunningham will lead Illumina's global commercial organization, overseeing marketing, sales, and customer service functions. CEO Jacob Thaysen emphasized his leadership skills and commitment to improving human health through innovation in genomics.
Read more →ILMNIllumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares Illumina, Inc. (NASDAQ: ILMN) today announced that its Board of Directors has approved the spin-off of GRAIL. GRAIL is anticipated to spin off from...
Illumina, Inc. has approved the spin-off of GRAIL, with the distribution set for June 24, 2024. Shareholders will receive one share of GRAIL for every six shares of Illumina they own. This decision marks a strategic move for Illumina, as they aim to enhance innovation in genomics while maintaining a 14.5% stake in GRAIL. The announcement outlines details regarding the distribution process and trading schedule for the new GRAIL stock on Nasdaq.
Read more →ILMNIllumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of its latest research being...
Illumina Inc. announced new research at the ASCO Annual Meeting highlighting the clinical utility of comprehensive genomic profiling (CGP) for oncology patients. The studies, presented in collaboration with Labcorp and others, underscore CGP's advantages in guiding therapy over single-gene testing. Additionally, Illumina showcased advancements in their molecular residual disease (MRD) assay, aiming to enhance testing accuracy and speed. The findings support a shift towards CGP as a standard care approach for improved patient outcomes in cancer treatment.
Read more →ILMNIllumina releases 2023 Corporate Social Responsibility Report Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its fifth annual Corporate Social...
Illumina Inc. has published its fifth annual Corporate Social Responsibility (CSR) Report, highlighting advancements made in 2023 towards improving human health. The report emphasizes the company's commitment to supporting patients, communities, employees, and environmental sustainability. CEO Jacob Thaysen reiterated Illumina's mission and the bold steps taken to enhance access to genomics while nurturing responsible business practices.
Read more →ILMNAnna Richo joins Illumina's Board of Directors Illumina, Inc. (NASDAQ: ILMN) announced today that Anna Richo has joined the company's Board of Directors following shareholder approval of the...
Illumina, Inc. has announced the appointment of Anna Richo to its Board of Directors, following shareholder approval. Richo brings over 30 years of legal, compliance, and regulatory experience from her previous roles at Cargill, UCB, and Amgen. CEO Jacob Thaysen expressed confidence that her expertise will aid Illumina in navigating the complexities of its expanding operations. Richo holds degrees from Cornell University and DePaul University College of Law and currently serves on several boards, demonstrating her commitment to governance and ethics.
Read more →ILMNIllumina To Webcast Upcoming Investor Conference Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Bernstein's 40th Annual...
Illumina, Inc. has announced that its executives will be participating in Bernstein's 40th Annual Investor Conference. The event will be accessible via a webcast, which will also offer a replay for at least 30 days after the conference. Illumina continues to focus on innovation in DNA sequencing and array-based technologies, aiming to enhance human health across various sectors, including life sciences and oncology.
Read more →ILMNIllumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL Illumina, Inc. (NASDAQ: ILMN) today announced that it has publicly filed a Form 10 registration statement with the U.S. Securities and Exchange...
Illumina, Inc. has publicly filed a Form 10 registration statement with the SEC in connection with its planned divestiture of GRAIL. This step is part of a broader divestment plan approved by the European Commission and aims to finalize terms by the end of Q2 2024. A favorable IRS ruling has been received enabling a tax-free distribution for U.S. shareholders. GRAIL will also host a Capital Markets Day on May 13, 2024, to discuss its business strategy and market opportunities.
Read more →ILMNIllumina To Webcast Upcoming Investor Conference Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: RBC 2024 Global Healthcare...
Illumina, Inc. (NASDAQ: ILMN) announced its executives will participate in the RBC 2024 Global Healthcare Conference. The webcast of the conference can be accessed through the Investor Info section of its website, with a replay available for 30 days following the event. Illumina emphasizes its role as a global leader in DNA sequencing and innovative technologies, serving various markets including life sciences and oncology.
Read more →ILMNIllumina Reports Financial Results for First Quarter of Fiscal Year 2024 Core Illumina revenue of $1.06 billion for Q1 2024, down 2% from Q1 2023 (down 2% on a constant currency basis) Core Illumina GAAP operating margin...
Illumina, Inc. reported its financial results for the first quarter of fiscal year 2024, indicating a slight decline in Core revenue, down 2% year-over-year. Despite improved gross margins and a significant increase in cash flow from operations, the company recorded an operating loss of $111 million. Looking ahead, Illumina forecasts that its revenue will be approximately flat compared to fiscal year 2023, as it continues to focus on its Core segment while addressing uncertainties surrounding GRAIL. The company also highlights innovations in technology that are driving customer engagement and increased sequencing activities.
Read more →ILMNIllumina's planned divestment of GRAIL approved by the European Commission Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its...
Illumina, Inc. has received approval from the European Commission for its divestment plan regarding GRAIL. This approval is an important milestone, allowing Illumina to explore options for divesting GRAIL either through a trade sale or a capital markets transaction. While the divestment method remains to be finalized, the company aims to complete the necessary arrangements by the end of the second quarter of 2024. The process involves securing approximately $1 billion in funding for GRAIL based on its long-range plan.
Read more →ILMNIllumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to...
Illumina, Inc. has announced the appointments of Ankur Dhingra as Chief Financial Officer and Jakob Wedel as Chief Strategy and Corporate Development Officer. Dhingra, who has a strong background in finance from previous roles in various biotech companies, will oversee the company's financial operations. Wedel, previously Chief of Staff, will focus on strategic planning and partnerships. The company has also reaffirmed its financial guidance for 2024 amid these leadership changes.
Read more →ILMNFor release
Illumina, Inc. has announced significant management changes, appointing Ankur Dhingra as Chief Financial Officer and Jakob Wedel as Chief Strategy and Corporate Development Officer. Dhingra, with extensive experience in life sciences and pharmaceuticals, will oversee financial aspects of the company. Wedel, who was previously Chief of Staff, will now focus on strategic planning and partnerships. Illumina has reaffirmed its financial guidance for the first quarter and full-year 2024 following these appointments.
Read more →ILMNIllumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024 Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the first quarter 2024 following the close of market on Thursday, May 2, ...
Illumina, Inc. announced that it will issue its financial results for the first quarter of 2024 on May 2, 2024, after the market closes. The company will host a conference call at 2:00 PM PT to discuss the results with analysts and investors. Interested parties can access the call via Illumina's website or by phone. The company maintains its position as a leader in DNA sequencing and array-based technologies, focusing on various life science applications.
Read more →ILMNIllumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023 Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis) Revenue of $4.50 billion for fiscal year 2023, down 2%...
Illumina, Inc. reported a revenue of $1.12 billion for Q4 2023, a 4% increase from the previous year, while fiscal year revenue decreased to $4.50 billion, down 2%. CEO Jacob Thaysen highlighted strong results driven by NovaSeq X instrument sales, despite ongoing customer purchasing constraints. The company emphasized its focus on operational excellence and addressing the GRAIL situation. Financial outlook for 2024 suggests that Core Illumina revenue is expected to be flat, while the GRAIL divestment timeline remains uncertain.
Read more →ILMNDocument Investors Salli Schwartz +1.858.291.6421 ir illumina.com Media David McAlpine +1.347.327.1336 pr illumina.com Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023 San Diego
Illumina, Inc. announced preliminary financial results for Q4 and fiscal year 2023, showing a 3% rise in Q4 revenue but a 2% drop for the full fiscal year compared to 2022. Core revenue also saw slight growth for Q4, although the overall fiscal year figures declined. The company shipped 79 NovaSeq X instruments in Q4 2023, indicating strong demand. However, operating margins remained negative for Q4 2023, and challenges integrating GRAIL continue to pose risks for the company.
Read more →ILMNIllumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023 Illumina, Inc. (Nasdaq: ILMN) ( Illumina or the company ) today announced unaudited preliminary financial results for the fourth quarter and fiscal ...
Illumina, Inc. has announced its preliminary financial results for the fourth quarter and fiscal year 2023, noting that these results are unaudited and subject to change. A detailed report is expected on February 8, 2024, following the scheduled J.P. Morgan Healthcare Conference presentation. The company provides non-GAAP measures to complement GAAP figures, emphasizing the complexity and risks involved in financial reporting. Illumina's performance and future projections will be influenced by external market conditions and internal operational challenges.
Read more →ILMNIllumina expands collaboration with Janssen to advance molecular residual disease cancer test Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has signed an agreement with Janssen ...
Illumina Inc. has announced a collaboration with Janssen Research & Development to advance its molecular residual disease (MRD) assay, which utilizes whole-genome sequencing to detect circulating tumor DNA. This innovative approach aims to provide a sensitive and accurate assessment of disease persistence or recurrence post-treatment. The collaboration seeks to create a cost-effective and automated testing solution with a rapid turnaround time of five to seven days. Illumina is also open to working with additional pharmaceutical partners to enhance the utility of the MRD assay in clinical research.
Read more →ILMNIllumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024 Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the fourth quarter and full year 2023 following the close of market on...
Illumina, Inc. will release its financial results for the fourth quarter and the entire year of 2023 on February 8, 2024. The announcement will be followed by a conference call featuring CEO Jacob Thaysen and CFO Joydeep Goswami at 2:00 PM PT. The call will be accessible via Illumina's website or through designated phone numbers. A replay of the call will be available for 30 days post-event, emphasizing Illumina's continued commitment to transparency and communication with stakeholders.
Read more →ILMNThe Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC...
Illumina Inc. (NASDAQ: ILMN) announced the addition of Bristol Myers Squibb, GSK, and Novo Nordisk to the Alliance for Genomic Discovery, enhancing collaborative drug discovery efforts. The alliance aims to co-fund the whole-genome sequencing of 250,000 DNA samples, focusing on action-oriented therapeutic targets. In 2023, the alliance completed sequencing approximately 86,000 genomes, including a significant diverse ancestry cohort. Leadership emphasizes the potential impact on human health through comprehensive genomic analysis, though challenges related to technology deployment and partnerships remain.
Read more →ILMN▲ +8.1%on this news
Illumina To Webcast Upcoming Investor Conference Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 42nd Annual J.P. Morgan...
Illumina, Inc. has announced that its executives will be speaking at the 42nd Annual J.P. Morgan Investor Conference. The webcast can be accessed via the company's Investor Info section and will also be available for replay for 30 days following the event. Known for its innovations in DNA sequencing, Illumina is marking 25 years of leadership in the genomics field, addressing segments such as life sciences and oncology.
Read more →ILMNIllumina Announces Decision to Divest GRAIL Today, Illumina, Inc. (NASDAQ: ILMN) announced that the company will divest GRAIL. The divestiture will be executed through a third-party sale or...
Illumina, Inc. (NASDAQ: ILMN) announced its decision to divest GRAIL, which will be executed via a third-party sale or capital markets transaction. This move is in accordance with a divestiture order from the European Commission, aiming to finalize the terms by the end of the second quarter of 2024. CEO Jacob Thaysen highlighted the company's commitment to ensuring GRAIL's technology benefits patients while also focusing on Illumina's core business and customer support. The announcement reflects Illumina's optimism regarding its future success and opportunities.
Read more →ILMNIllumina submits Form 10 to the Securities and Exchange Commission Illumina, Inc. (NASDAQ: ILMN) has confidentially submitted a draft registration statement on Form 10 related to its potential divestiture of GRAIL to ...
Illumina, Inc. (NASDAQ: ILMN) has confidentially submitted a draft registration statement on Form 10 to the U.S. Securities and Exchange Commission. This step is part of Illumina's compliance with an order from the European Commission requiring the divestiture of GRAIL. The company aims to evaluate multiple divestiture options to optimize outcomes for shareholders and GRAIL. Illumina is supported by financial and legal advisors throughout this process.
Read more →ILMN▲ +5.1%on this news
Illumina To Webcast Upcoming Investor Conferences Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: Evercore ISI 6th Annual...
Illumina, Inc. (NASDAQ: ILMN) has announced that its executives will participate in several upcoming investor conferences. The webcasts of these events will be available on Illumina's Investor Info webpage, with replays accessible for at least 30 days post-event. Celebrating its 25th anniversary, Illumina underscores its role as a leader in DNA sequencing and array-based technologies across various markets.
Read more →ILMN▼ -5.7%on this newsshared move
Illumina ने निम्न और मध्यम आय वाले देशों में रोगजनक अनुक्रमण में तेज़ी का समर्थन करने के लिए ग्लोबल हेल्थ एक्सेस इनिशिएटिव लॉन्च किया Illumina Inc. (NASDAQ: ILMN), DNA अनुक्रमण और सरणी-आधारित तकनीकों में एक ग्लोबल लीडर, ने आज निम्न और मध्यम आय वाले देशों (LMICs) में सार्वजनिक...
Illumina Inc. has launched a Global Health Access Initiative aimed at improving genomic sequencing in low- and middle-income countries (LMICs). This initiative focuses on enhancing health outcomes through better access to genomic data and collaboration with organizations like FIND and the Global Fund. The program seeks to address significant health challenges by providing advanced genomic tools and resources.
Read more →ILMN▼ -5.7%on this newsshared move
Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access...
Illumina has launched the Global Health Access Initiative to enhance genomic sequencing capabilities in low- and middle-income countries. This initiative aims to provide reduced pricing and tackle logistical barriers to access pathogen sequencing tools necessary for public health. By promoting local sequencing capabilities, it seeks to strengthen health systems and improve responses to health threats. The program aligns with global health strategies to enhance preparedness for future pandemics.
Read more →ILMNIllumina Reports Financial Results for Third Quarter of Fiscal Year 2023 Welcomed new CEO Jacob Thaysen, Ph.D., who started with Illumina on September 25, 2023 With respect to GRAIL, continue to proceed quickly: retained...
Illumina, Inc. reported its financial results for the third quarter of 2023 with revenues of $1,119 million, reflecting stable performance compared to the previous year. The company announced substantial goodwill and intangible asset impairment related to the GRAIL segment, totaling $821 million, primarily driven by a decrease in market capitalization. New CEO Jacob Thaysen emphasized the importance of optimizing operations and stimulating demand for the NovaSeq X. Looking ahead, Illumina anticipates a revenue decline of 2% to 3% for the fiscal year, alongside an expected diluted loss per share of $(6.67) to $(6.57).
Read more →ILMNIllumina launches advanced liquid biopsy assay to enable comprehensive genomic profiling of solid tumors Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation of its distributed...
Illumina Inc. has announced the launch of the TruSight Oncology 500 ctDNA v2 assay, enhancing the ability to conduct noninvasive comprehensive genomic profiling using circulating tumor DNA. Key improvements include reduced turnaround times and heightened sensitivity for lower DNA input, aimed at better supporting cancer research and clinical needs. Nine institutions are already participating in an early-access program to trial this advanced technology, which is expected to become more automated in 2024. This development signifies a shift in oncology towards more accessible testing methods that could alleviate the dependency on traditional tissue biopsies.
Read more →ILMNIllumina responds to European Commission's divestiture order Illumina, Inc. (NASDAQ:ILMN), has received an order from the European Commission (EC) directing the company to divest GRAIL. Receipt of the order is...
Illumina, Inc. has received an order from the European Commission to divest GRAIL. The company is committed to resolving this issue and maximizing shareholder value through flexible transaction structures. Illumina will have twelve months to complete the divestiture, while continuing to fund GRAIL. Additionally, the company is challenging the Commission's jurisdiction over the acquisition in the European Court of Justice.
Read more →ILMNIllumina Posted a Stewardship-Focused Presentation for Investors Illumina, Inc. (NASDAQ:ILMN) posted a stewardship-focused presentation for investors on the Events & Presentations section of its investor relations...
Illumina, Inc. (NASDAQ: ILMN) recently released a stewardship-focused presentation for investors on its investor relations website. This presentation, aimed at facilitating discussions, features contributions from members of the company's Board of Directors and senior management. Celebrating 25 years of innovation, Illumina has established itself as a leader in DNA sequencing and related technologies, impacting various markets including life sciences and oncology.
Read more →ILMNIllumina to Announce Third Quarter 2023 Financial Results on Thursday, November 9, 2023 Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the third quarter 2023 following the close of market on Thursday,...
Illumina, Inc. has announced that it will disclose its financial results for the third quarter of 2023 after market close on November 9, 2023. A conference call will be held at 2:00 PM Pacific Time to discuss these results with analysts and investors. This announcement coincides with the company's 25th anniversary, highlighting its leadership in DNA sequencing and array-based technologies across various markets.
Read more →ILMN▼ -5.4%on this news
Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer
Illumina, a leader in DNA sequencing technology, has appointed Jacob Thaysen, Ph.D., as its new Chief Executive Officer effective September 25, 2023. Thaysen has a strong background in genomics and life sciences, previously serving as senior vice president at Agilent Technologies. His track record in driving revenue growth and transforming analytical lab environments is seen as a significant asset for Illumina. The leadership transition is expected to propel the company into its next phase of growth.
Read more →ILMN▼ -5.4%on this news
Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has...
Illumina, Inc. has appointed Jacob Thaysen, Ph.D., as its new Chief Executive Officer, effective September 25, 2023. Thaysen, who has a strong background in genomics and life sciences from his previous role at Agilent Technologies, will be a key figure in guiding Illumina into its next phase of growth. The company believes that Thaysen's technological expertise and successful track record will help enhance shareholder value and meet corporate goals. Charles Dadswell, the interim CEO, will return to his previous role as Senior Vice President and General Counsel.
Read more →ILMNIllumina To Webcast Upcoming Investor Conference Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Morgan Stanley 21st Annual...
Illumina, Inc. announced that its executives will participate in the Morgan Stanley 21st Annual Investor Conference. The event will be accessible via a webcast on Illumina's website, with a replay available for 30 days after the conference. Celebrating 25 years of innovation, Illumina continues to lead in DNA sequencing and array-based technologies across various markets.
Read more →ILMNIllumina expands genomics capabilities in India with opening of Solutions Center Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the opening of a new office and...
Illumina Inc. has announced the opening of a new Solutions Center in Bengaluru, India, marking a significant expansion of its operations in the region. This move is aimed at enhancing access to genomics and bolstering collaborations within India's burgeoning biotech ecosystem. The company plans to work closely with local partner Premas Life Sciences and has a history of supporting important health initiatives like tuberculosis surveillance and COVID-19 testing. This expansion is aligned with Illumina's commitment to increasing diversity in genomic data and fostering equitable access to genomic technologies.
Read more →ILMNIllumina To Webcast Upcoming Investor Conference Illumina, Inc. (NASDAQ: ILMN) today announced that its vice president of investor relations will be speaking at the following investor conference:...
Illumina, Inc. (NASDAQ: ILMN) has announced that its vice president of investor relations will present at an upcoming investor conference. The webcast will be accessible through the Investor Info section on Illumina's website, with a replay available for at least 30 days post-event. The company highlights its 25 years of innovation and leadership in DNA sequencing and array-based technologies.
Read more →ILMNDr. Steven Barnard Appointed Chief Technology Officer Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Dr. Steven Barnard, Illumina's Vice...
Illumina, Inc. has appointed Dr. Steven Barnard as its new Chief Technology Officer, effective immediately. Dr. Barnard, who has been with the company since 1998 and has played critical roles in its R&D, succeeds Dr. Alex Aravanis, who is leaving for another opportunity. With a strong background in technology development and innovation, Barnard aims to enhance R&D efficiency and drive shareholder value. His leadership and insights are expected to further Illumina's mission to improve human health through advanced DNA sequencing technologies.
Read more →ILMNIllumina Reports Financial Results for Second Quarter of Fiscal Year 2023 Revenue of $1.18 billion for Q2 2023, up 1% from Q2 2022 (up 3% on a constant currency basis) and up 8% from Q1 2023 Shipped 109 NovaSeq X...
Illumina, Inc. announced its financial results for Q2 2023, reporting consolidated revenue of $1.18 billion, a 1% increase from Q2 2022. The company experienced an 8% sequential revenue growth due to increased NovaSeq X shipments. However, the outlook for the second half of the year includes anticipated revenue challenges due to customer caution and a slower recovery in China. Additionally, a notable decline in high throughput consumables is expected as customers transition to NovaSeq X.
Read more →ILMNIllumina and Pillar Biosciences partner to improve access to personalized cancer treatment options Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the pioneers of Decision...
Illumina Inc. and Pillar Biosciences Inc. have announced a partnership to enhance access to personalized cancer treatment options. Illumina will leverage Pillar's targeted sequencing technology in conjunction with its own sequencing and bioinformatics solutions. The collaboration aims to enable rapid genomic profiling of tumors, which is critical for personalized therapy. Commercial availability of the oncology assays through Illumina is expected to begin this month.
Read more →ILMNIllumina to Announce Second Quarter 2023 Financial Results on Wednesday, August 9, 2023 Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2023 following the close of market on Wednesday,...
Illumina, Inc. (NASDAQ: ILMN) is set to announce its financial results for the second quarter of 2023 on Wednesday, August 9, 2023, following the market's close. A conference call will be hosted by Interim CEO Charles Dadswell and CFO Joydeep Goswami at 2:00 PM Pacific Time to discuss the results. The call can be accessed via Illumina's website or by dialing into a dedicated conference line. Illumina continues to mark its 25 years of innovation in the field of DNA sequencing.
Read more →ILMNThe Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC, a...
Illumina Inc. has announced the formation of the Alliance for Genomic Discovery, which includes founding members AbbVie, Amgen, AstraZeneca, Bayer, and Merck. This multiyear initiative aims to enhance therapeutic development through large-scale whole-genome sequencing of 250,000 samples, focusing on increasing diversity in genomic data. The collaboration with Nashville Biosciences will leverage advanced sequencing technologies to identify disease associations. Despite its potential, the project faces challenges, including multiparty collaboration dynamics and technological development hurdles.
Read more →ILMNIllumina DRAGEN™ 4.2 delivers most accurate and comprehensive coverage of the genome, powering greater applications and discovery Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of the latest version of...
Illumina Inc. has announced the launch of DRAGEN 4.2 software, enhancing the analysis of next-generation sequencing data. This new version offers improved accuracy, flexibility, and scalability, enabling better insights into genomic data. Key features include advancements in identifying genetic diseases and drug discovery, particularly in cardiovascular health. Early access partner Fritz Sedlazeck highlights its potential to facilitate significant advancements in genomic analysis.
Read more →ILMNIllumina announces CEO transition plan
Illumina has announced the resignation of CEO Francis deSouza, effective June 11, 2023, with Charles Dadswell stepping in as interim CEO. The Board of Directors expressed gratitude for deSouza's leadership and is actively searching for a new permanent CEO. DeSouza will continue to serve in an advisory role until the end of July 2023. The Board aims to find a leader capable of advancing healthcare and enhancing shareholder value.
Read more →ILMNIllumina announces CEO transition plan Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of Directors has...
Illumina Inc. has announced the resignation of its CEO, Francis deSouza, effective June 11, and named Charles Dadswell as interim CEO. The Board of Directors is initiating a search for a new CEO, focusing on candidates who can drive growth and shareholder value. DeSouza will remain in an advisory role until July 31, 2023. The Board expressed appreciation for deSouza's contributions while emphasizing ongoing advancements in the company's DNA sequencing technology.
Read more →ILMNIllumina releases 2022 Corporate Social Responsibility Report Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its annual Corporate Social...
Illumina Inc. has released its 2022 Corporate Social Responsibility (CSR) Report, which underscores the company's ongoing commitment to improving global health and sustainability. The report details advancements made in Illumina's environmental, social, and governance (ESG) program across five key areas. CEO Francis deSouza emphasized the potential of genomics to enhance healthcare, promote equity, and advance personalized medicine. The company is scheduled to host a virtual ESG Investor Event to further discuss its initiatives.
Read more →ILMNIllumina's Board of Directors elects two experienced Independent Directors to Board Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of governance changes...
Illumina, Inc. has appointed two new independent directors to its Board, Stephen P. MacMillan and Scott B. Ullem, as part of strategic governance changes aimed at strengthening leadership. MacMillan serves as CEO of Hologic and brings extensive experience in healthcare, while Ullem is CFO of Edwards Lifesciences with a strong financial background. These changes are expected to enhance the board's capabilities in corporate finance and international expansion, ultimately benefiting shareholder value. Additionally, Sue Siegel has been appointed as Chair of the Compensation Committee.
Read more →ILMNIllumina unveils AI software to predict disease-causing genetic mutations in patients Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the new PrimateAI-3D, an artificial...
Illumina Inc. has announced the launch of PrimateAI-3D, an advanced AI algorithm designed to predict disease-causing genetic mutations in patients with unprecedented accuracy. This tool, grounded in research published in Science, utilizes deep neural networks trained on the DNA of diverse primate species to identify disease-linked genetic variants. PrimateAI-3D is expected to enhance the precision of personalized genomic medicine and accelerate drug target discovery. The algorithm will be accessible to the genomics community and is part of Illumina's ongoing commitment to innovation in genetic research.
Read more →ILMNIllumina to Host Third Annual Virtual ESG Investor Event on Monday, June 12, 2023 Illumina, Inc. (NASDAQ: ILMN) announced today that it will host its third annual virtual Environment, Social and Corporate Governance (ESG) focused...
Illumina, Inc. announced the hosting of its third annual virtual ESG investor event on June 12, 2023. Key executives, including the CEO and CFO, will present on Illumina's ESG strategies and action plans. The event will also include a fireside chat and a Q&A session for participants, demonstrating Illumina's commitment to corporate governance and transparency. Interested parties can register and attend the live event through the company's investor website.
Read more →ILMNReal-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of the latest data on the impact...
Illumina Inc. has announced real-world study data demonstrating the benefits of comprehensive genomic profiling (CGP) for cancer patients, showcasing improved survival rates compared to standard chemotherapy. The findings, to be presented at the ASCO Annual Meeting, also reveal significant shortcomings in current standard-of-care testing, with many eligible patients lacking access to effective genomic testing. Additional studies emphasize the need for better adoption of CGP to enhance patient outcomes in oncology.
Read more →ILMN▼ -9%on this newsshared move
Illumina Announces Preliminary Results of Annual Meeting Illumina shareholders re-elect eight of nine Illumina directors SAN DIEGO, May 25 , 2023 /PRNewswire/ -- Illumina (NASDAQ: ILMN), a global leader in DNA sequencing
Illumina has announced preliminary results from its 2023 Annual Meeting, where shareholders re-elected eight of nine directors, including new board member Andrew Teno. The company received positive votes for various proposals, but notably, the say-on-pay proposal was not approved. These results are preliminary and await final certification by an independent Inspector of Elections. Illumina expressed gratitude to shareholders for their support and emphasized transparency and communication moving forward.
Read more →ILMNIllumina Board Chair issues letter to shareholders and urges shareholders to vote the WHITE proxy card FOR all nine of Illumina's nominees Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today issued a shareholder letter from Board Chair John...
Illumina's Board Chair, John Thompson, has issued a letter encouraging shareholders to vote in favor of all nine nominees on the WHITE proxy card ahead of the upcoming Annual Meeting on May 25, 2023. The letter outlines the company's commitment to addressing shareholder feedback and improving financial performance, as current results have not met expectations. Thompson's communication reflects a strong intent to uphold governance priorities and enhance accountability within the organization.
Read more →ILMNIllumina's genomic technologies enable better pathogen preparedness and response Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today recognized the progress and impact of genomic...
Illumina Inc. has recognized the vital role of genomic technologies in enhancing pathogen preparedness and response, particularly following advances made during the COVID-19 pandemic. The company’s genomic surveillance solutions have enabled public health agencies to track and respond to a range of pathogens more effectively. As global health systems recover from the pandemic, Illumina's initiatives aim to maintain vigilance against future threats through enhanced surveillance and rapid response capabilities. Furthermore, efforts are underway to expand genomic technology access to regions previously underserved, such as Africa and Latin America.
Read more →ILMNIllumina sends letter to shareholders detailing why Illumina's nominees far outmatch Icahn's slate in skills and experience Illumina's director nominees bring deep commercial, scientific and business experience from leading organizations including Microsoft, Symantec, and...
Illumina has sent a shareholder letter emphasizing the superior qualifications of its board nominees over those proposed by Carl Icahn. The letter highlights a recommendation from Institutional Shareholder Services in favor of Illumina's slate and denotes ongoing governance issues at Icahn's firm, which is currently under federal investigation. Illumina aims to maintain its competitive edge with a robust strategy focused on financial growth and innovation. The annual meeting for shareholder voting is scheduled for May 25, 2023.
Read more →ILMNLeading Proxy Advisory Firm ISS Recommends Illumina Shareholders Vote FOR Eight of Illumina's Highly Qualified Director Nominees Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Institutional Shareholder Services...
Illumina (NASDAQ: ILMN) announced that Institutional Shareholder Services (ISS) has recommended shareholders vote in favor of its CEO Francis deSouza and Board member Robert Epstein during the upcoming Annual Meeting. ISS's endorsement highlights the strength of Illumina's Board and its governance practices while advising shareholders to reject two nominees associated with Carl Icahn. The report also notes Icahn Enterprises is currently under investigation by federal authorities, adding a layer of complexity to the voting situation. Illumina's Board urges shareholders to protect their investments by supporting all nine nominated directors.
Read more →ILMNIllumina Sends Letter to Shareholders Highlighting Board Strength, Weakness of Icahn's Plan Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today issued a shareholder letter highlighting the strength...
Illumina has issued a letter to shareholders highlighting the strength of its Board and urging them to vote for its nine director nominees while rejecting the three nominees proposed by investor Carl Icahn. The company claims that Icahn's plan lacks substance and understanding of the genomics industry. Illumina maintains confidence in its strategy for long-term growth and value delivery. The Annual Meeting is set for May 25, 2023, and shareholders are encouraged to utilize the WHITE proxy card for voting.
Read more →ILMNIllumina increases equitable access to STEM education, reaching over 1 million learners Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced outcomes from its annual The Future Is...
Illumina Inc. has announced the outcomes of its annual 'The Future Is Bright' genomic literacy initiative, which has now reached over 1.2 million learners across 11 countries. The initiative aims to improve equitable access to STEM education and includes activities such as career panels and free science kits for students. This year, 100,000 learners were engaged in April alone, and the program has expanded to regions including Japan and South Korea. Illumina aims to reach 5 million STEM learners globally by 2030.
Read more →ILMNIllumina Issues Shareholder Letter and Requests Shareholders Vote for the Illumina Director Nominees on the WHITE Proxy Card Strong NovaSeqTM X shipments drove solid Illumina first quarter results; company commits to grow Core Illumina non-GAAP operating margins to 27%[1]...
Illumina issued a shareholder letter emphasizing its focus on long-term value creation and promoting its board nominees. The company reported strong first-quarter results driven by increased demand for its NovaSeq TM X. Illumina has committed to raising its operating margins to 27% by 2025 while implementing more than $100 million in annual cost savings. Additionally, its GRAIL subsidiary shows promising growth, particularly with its multi-cancer detection test, Galleri.
Read more →ILMNIllumina Reports Financial Results for First Quarter of Fiscal Year 2023; Announces Commitment to Accelerate Margin Growth Revenue of $1.09 billion for Q1 2023, up 1% from Q4 2022; down 11% from Q1 2022 (down 9% on a constant currency basis) GAAP diluted EPS of $0.02 for...
Illumina, Inc. reported its financial results for the first quarter of 2023, revealing a revenue drop to $1.09 billion, down 11% from the prior year. The company highlighted strong demand for its NovaSeq X sequencing platforms, which outperformed expectations. Despite the positive demand, Illumina encountered challenges with operating profit and margins, with a loss of $64 million reported. The firm is committed to a cost-saving initiative expected to free up over $100 million, aiming for higher margins in the coming years.
Read more →ILMNIllumina Urges Shareholders to Vote the WHITE Proxy Card FOR all Nine of Illumina's Nominees Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today urged shareholders to vote in favor of...
Illumina, Inc. (NASDAQ: ILMN) has urged shareholders to vote for its slate of director nominees at the upcoming Annual Meeting on May 25, 2023. The company is encouraging shareholders to use the WHITE proxy card to support all nine nominees, highlighting their qualifications and experience. Illumina's Board believes that the election of Carl Icahn's nominees would jeopardize the long-term strategy and interests of Illumina's shareholders. The company positions itself as dedicated to delivering sustainable growth and shareholder value.
Read more →ILMNIllumina's cloud-based informatics programs recognized for robust, international data privacy protections Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received the international...
Illumina Inc. has achieved international privacy certification for six of its cloud-based informatics programs under ISO/IEC 27701. This certification demonstrates Illumina's commitment to robust data privacy protections, especially in handling sensitive genomic data. With a focus on security, the company aims to help clients comply with global data privacy standards and protect against cyber threats. Illumina's certification builds on its previous ISO/IEC 27001 certification, emphasizing its leadership in the DNA sequencing technology space.
Read more →ILMNIllumina and Henry Ford Health team up to study impact of comprehensive genomic testing for cardiovascular patients Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Henry Ford Health, a not-for-profit health care...
Illumina Inc. has partnered with Henry Ford Health to evaluate the effect of comprehensive genomic testing on cardiovascular patients. The initial study, named CardioSeq, will involve 1500 participants to analyze how whole-genome sequencing impacts medical management and clinical outcomes. The collaboration emphasizes the integration of genomic testing into standard care, especially for underserved populations, along with exploring cost implications. Their findings are expected to enhance understanding and treatment of genetic contributors to cardiovascular diseases.
Read more →ILMNIllumina celebrates 25 years of innovation Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today begins a monthlong celebration of its 25th...
Illumina Inc. marks its 25th anniversary by reflecting on its contributions to DNA sequencing and personalized health. The company celebrates its global presence and workforce while emphasizing its commitment to advancing genomics and improving human health. CEO Francis deSouza and founder David Walt express excitement for the future of genomics and the impact of their innovations. As part of this milestone, Illumina will also initiate a philanthropic grant program to support local nonprofits where it operates.
Read more →ILMNIllumina to Announce First Quarter 2023 Financial Results on Tuesday, April 25, 2023 Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2023 following the close of market on Tuesday, April...
Illumina, Inc. has announced the release date for its first quarter 2023 financial results, which will occur on April 25, 2023, after market close. A conference call will follow, led by CEO Francis deSouza and CFO Joydeep Goswami, allowing for discussions with analysts and investors. This event highlights the company's ongoing commitment to transparency and stakeholder engagement.
Read more →ILMNIllumina's revolutionary NovaSeq X exceeds 200th order milestone in first quarter 2023 Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has already exceeded more than 200...
Illumina Inc. reported that its NovaSeq X sequencing system surpassed 200 orders in the first quarter of 2023, highlighting strong global demand across various customer segments. With capabilities for rapid and accurate sequencing, the NovaSeq X aims to enhance multiomic analyses and support a variety of genomic projects. It represents a significant advancement over previous models, enabling cost-effective generation of genomic data. Illumina continues to prioritize supporting customer needs and fostering the adoption of whole-genome sequencing worldwide.
Read more →ILMNIllumina Will Appeal FTC Decision in Federal Court, Will Seek US Resolution by Late 2023 or Early 2024 Illumina, Inc. (NASDAQ: ILMN) today announced that it will appeal the Federal Trade Commission's ( FTC ) decision ordering the unwinding of...
Illumina, Inc. plans to appeal the FTC's decision to unwind its acquisition of GRAIL, seeking a resolution by late 2023 or early 2024. The company aims to maximize shareholder value while expanding the Galleri test's presence in the multi-cancer screening market. If Illumina does not succeed in the appeal, it will expedite the divestiture of GRAIL, ensuring that it acts in the best interests of its shareholders. The appeal process entails inherent risks and uncertainties, particularly regarding the integration of GRAIL's business and the commercial success of Galleri.
Read more →ILMNIllumina Files Preliminary Proxy, Urging Shareholders to Vote for Its Director Nominees and Withhold for Each Icahn Group Nominee Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today filed its preliminary proxy statement with the...
Illumina has filed a preliminary proxy statement urging shareholders to support its current Board of Directors and withhold votes for three nominees proposed by activist investor Carl Icahn. The company argues that Icahn's nominees lack the necessary skills and understanding of its business, posing risks to its long-term strategy. Despite attempts from Illumina's management to meet with Icahn and his nominees, the discussions did not lead to constructive engagement. The company aims to highlight the strengths of its current Board as it prepares for the Annual Meeting of Shareholders.
Read more →ILMNIllumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the release of Connected Insights, a...
Illumina Inc. has launched Connected Insights, a cloud-based software intended for tertiary analysis of clinical next-generation sequencing (NGS) data. The software aims to enhance the efficiency of interpreting and reporting genomic data, particularly for somatic oncology applications, with plans to support rare diseases in the future. The release follows a growing demand for comprehensive genomic profiling and reflects the company's efforts to standardize genomic data analysis across various test types. The product is currently in limited release and undergoing beta testing in the US.
Read more →ILMNIllumina Issues Statement in Response to Carl Icahn's Letter Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, issued the following statement in response to a letter ...
Illumina, Inc. has issued a statement in response to a letter from investor Carl Icahn, asserting the independence of its Board of Directors and its commitment to shareholder interests. The company defends its transparent disclosure practices, particularly regarding corporate risk factors, including those associated with GRAIL. Icahn's criticisms include questioning the qualifications of his nominees for Illumina's Board and the company's ability to navigate complex regulatory processes.
Read more →ILMNIllumina Underscores Commitment to Shareholder Value and Responds to Carl Icahn's Statements Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today issued the following response to Carl Icahn's public...
Illumina responded to Carl Icahn's recent criticisms, reaffirming its commitment to shareholder value and emphasizing its successful track record in genomics innovation. The company highlighted its profitability and market leadership, noting the impressive demand for its latest sequencing platform, NovaSeq X, and the promising revenue prospects for its GRAIL product, Galleri. While Icahn's involvement raises concerns regarding board composition due to his nominees’ lack of relevant experience, Illumina maintains that its current board is well-equipped to drive the company's long-term growth and navigate regulatory challenges. Furthermore, the company aims to maximize the potential value of GRAIL amid ongoing legal discussions.
Read more →ILMNIllumina launches its first product enabling long- and short-read sequencing on one instrument Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first product based on its...
Illumina Inc. has launched its first product utilizing Illumina Complete Long Read technology, allowing simultaneous long- and short-read sequencing on existing NovaSeq systems. This advancement aims to improve workflow efficiency and reduce DNA input requirements for genomic labs. Early customer data indicates high accuracy and operational flexibility, bolstering Illumina's position as a leader in DNA sequencing. The company also plans future applications and enhancements in long-read technology.
Read more →ILMN▲ +17%on this newsshared move
Illumina Responds to Icahn Partners' Nomination of Directors Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies, confirmed today that it has received notice from Icahn ...
Illumina, Inc. has confirmed its receipt of director nominations from Icahn Partners, prompting a commitment to engage with shareholders. However, Illumina's Board found the nominees lack relevant skills, opting to recommend against their election. Concurrently, Illumina continues its divestiture work related to GRAIL, aiming to enhance shareholder value while promoting its innovative products. The company emphasizes its independence and experience in governance.
Read more →ILMNIllumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Myriad Genetics Inc. (NASDAQ: MYGN), a leader in...
Illumina Inc. and Myriad Genetics have expanded their strategic partnership to enhance access to homologous recombination deficiency (HRD) testing in the United States. The collaboration combines both companies' technologies to launch the TSO 500 HRD test, aimed at improving the identification of genetic variants associated with several types of cancer. This development is expected to support clinical research and accelerate advancements in cancer treatment. The new test is already available for order and could significantly impact patient care by providing a comprehensive analysis from a single sample.
Read more →ILMNIllumina To Webcast Upcoming Investor Conference Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 43rd Annual Cowen Health...
Illumina, Inc. (NASDAQ: ILMN) announced its participation in the 43rd Annual Cowen Health Conference, where its executives will present. The webcast of the conference will be available on Illumina's Investor Info section and will offer a replay for at least 30 days following the event. This engagement reflects Illumina's ongoing commitment to transparency and investor relations.
Read more →ILMNIllumina liefert erstes NovaSeq X Plus-Sequenziergerät an das Broad Institute Illumina Inc. (NASDAQ: ILMN), ein weltweit führender Anbieter von DNA-Sequenzierungs- und Array-Technologien, gab heute bekannt, dass sein erstes...
Illumina Inc. has announced the delivery of its first NovaSeq X Plus sequencing system to the Broad Institute during the AGBT conference in Hollywood, Florida. This new system is touted as the company's most powerful sequencing technology to date, boasting high throughput, accuracy, and sustainability features that meet significant expectations from genomic researchers. Alex Aravanis, CTO of Illumina, highlighted this milestone, emphasizing its capacity to enable groundbreaking genomic projects. Additionally, Illumina's Complete Long Reads technology was discussed, which promises to improve long-read sequencing efficiently.
Read more →ILMN▼ -8%on this newsshared move
Illumina delivers first NovaSeq X Plus sequencer to the Broad Institute Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first NovaSeq X Plus system...
Illumina Inc. has delivered its first NovaSeq X Plus sequencer to the Broad Institute, highlighting advancements in DNA sequencing technology. During the AGBT conference, CTO Alex Aravanis discussed additional innovations, including Illumina Complete Long Reads, which efficiently produces accurate long reads. The Broad Institute anticipates that the new sequencing platform will enhance their genomic research capabilities. Illumina plans to ship more than 300 instruments in total this year, marking a significant step in their operational growth.
Read more →ILMN▼ -8%on this newsshared move
Illumina livre le premier séquenceur NovaSeq X Plus au Broad Institute Illumina Inc. (NASDAQ: ILMN), un leader mondial dans le séquençage de l'ADN et les technologies basées sur les analyses, a annoncé aujourd'hui que...
Illumina Inc. has announced the delivery of its first NovaSeq X Plus sequencing system to the Broad Institute, achieving a significant milestone in genomic research technology. The system's performance is reported to equal or exceed that of the previous NovaSeq 6000. At the AGBT conference, Illumina provided insights into its NovaSeq technology and the new Illumina Complete Long Reads, which aims to streamline genomic sequencing workflows. The company anticipates shipping 40 to 50 units this quarter and over 300 in total within the year.
Read more →ILMN▼ -8%on this newsshared move
Illumina entrega el primer secuenciador NovaSeq X Plus al Broad Institute Illumina Inc. (NASDAQ: ILMN), líder global en secuenciación de ADN y tecnologías basadas en matrices, anunció hoy que su primer sistema NovaSeq X...
Illumina Inc. announced the first delivery of its NovaSeq X Plus sequencer to the Broad Institute at the AGBT conference in Hollywood, Florida. This delivery marks the beginning of a new era in genomic research, promising higher performance and cost-effective solutions. Illumina also revealed updates on its innovative Complete Long Reads technology, which provides long, accurate reads with minimal DNA input. The company aims to enhance genomic capabilities and support extensive research projects with its advanced offerings.
Read more →ILMN▼ -8%on this newsshared move
Illumina entrega primeiro sequenciador NovaSeq X Plus para Broad Institute A Illumina Inc. (NASDAQ: ILMN), líder mundial em sequenciamento de DNA e tecnologias baseadas em matrizes, anunciou hoje que seu primeiro sistema...
A Illumina Inc. anunciou a entrega do primeiro sistema NovaSeq X Plus ao Broad Institute, destacando um marco importante em tecnologia de sequenciamento de DNA. Durante a conferência AGBT, a empresa também revelou avanços na Illumina Complete Long Reads, que promete oferecer sequências longas com alta precisão. Aravanis, diretor de tecnologia da Illumina, manifestou otimismo sobre o potencial da nova plataforma em atender demandas crescentes em pesquisa genômica. Com a previsão de enviar mais de 300 instrumentos ao longo do ano, a Illumina está em uma posição forte para impulsionar a inovação no setor.
Read more →ILMNIllumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022 Revenue of $1.08 billion for Q4 2022, down 10% from Q4 2021, and down 7% on a constant currency basis Revenue of $4.58 billion for fiscal year 2022,...
Illumina, Inc. reported its financial results for the fourth quarter and fiscal year 2022, highlighting a revenue drop of 10% in Q4 compared to the previous year. The results included a significant goodwill impairment of $3.91 billion related to its GRAIL segment. Despite the challenges, the company noted strong interest in its NovaSeq X sequencer and an increase in orders for the Galleri test from GRAIL. Looking ahead, Illumina is forecasting revenue growth between 7% and 10% for 2023.
Read more →ILMNDocument Illumina Appoints Joydeep Goswami Chief Financial Officer
Illumina has appointed Joydeep Goswami as Chief Financial Officer, transitioning from his role as Chief Strategy and Corporate Development Officer. Goswami has been with Illumina since 2019 and has over 20 years of experience in the life sciences industry. He aims to enhance the company's financial operations and maximize shareholder value. Illumina's leadership expresses confidence in his capabilities to drive continued growth and profitability.
Read more →ILMNIllumina Appoints Joydeep Goswami Chief Financial Officer Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami has been appointed...
Illumina, Inc. has appointed Joydeep Goswami as its new Chief Financial Officer, effective immediately. Goswami, who previously served as the Chief Strategy and Corporate Development Officer, will oversee financial planning, accounting, investor relations, and other financial operations of the company. With over 20 years of experience in the life sciences sector, his appointment is seen as beneficial for driving growth. Illumina's CEO praised Goswami's leadership qualities and industry knowledge, positioning him as a key figure in advancing the company's mission.
Read more →ILMNDocument CORPORATE PARTICIPANTS Francis A. deSouza Illumina,Inc. - CEO Director Joydeep Goswami Illumina, Inc.- Chief Strategy Corporate Development Officer and Interim CFO CONFERENCE CALL PARTICIPANTS Ruizhi Qin JPMorga
Illumina, Inc. has shared its strategic outlook during a recent conference call, highlighting its mission to integrate genomic sequencing into standard clinical care. CEO Francis deSouza discussed the company's strong revenue performance and its innovative NovaSeq X sequencer, which promises enhanced efficiency and lower costs. Despite a positive forecast for revenue growth in 2023 and impressive demand for its products, Illumina faces financial challenges related to GRAIL, which is expected to operate at a loss in the near term due to ongoing investments and regulatory requirements.
Read more →ILMN▼ -6.2%on this newsshared move
Illumina to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023 Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2022 following the close of market on...
Illumina, Inc. has announced that it will release its fourth quarter and full year 2022 financial results on February 7, 2023. A conference call will be held the same day at 2:00 PM Pacific Time with key executives, including the CEO. Investors and analysts can access the call and subsequently find a replay available for 30 days. Illumina continues to focus on innovation in DNA sequencing and array-based technologies across various markets.
Read more →ILMNIllumina and Nashville Biosciences Announce Sequencing Agreement with Amgen Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Nashville Biosciences LLC, a wholly owned...
Illumina Inc. and Nashville Biosciences have collaborated on an agreement with Amgen to conduct whole-genome sequencing of approximately 35,000 DNA samples, predominantly from African Americans. This initiative seeks to address the underrepresentation of diverse populations in genomic research and aims to create the largest dataset of its kind. The project is part of a broader multiyear effort to accelerate therapeutic development through extensive genomic data, with insights expected to impact drug discovery and health disparities among underrepresented groups.
Read more →ILMNIllumina To Webcast Upcoming Investor Conference Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 41st Annual J.P. Morgan...
SAN DIEGO , Dec. 19, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that its executives will be speaking at the following investor conference: The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com . A re
Read more →ILMNIllumina Ranks Among Top Scores on Dow Jones Sustainability Index and CDP Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced its achievement of the highest score...
As of December 9, 2022 Illumina awarded highest score from S&P Dow Jones Indices in Life Sciences Tools & Services Sector Illumina received leadership score with an A- from CDP SAN DIEGO , Dec. 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequ
Read more →ILMNIllumina To Webcast Upcoming Investor Conferences Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: Evercore ISI HealthCONx...
SAN DIEGO , Nov. 15, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that its executives will be speaking at the following investor conferences: The webcasts can be accessed through the Investor Info section of Illumina's website at investor.illumina.com . A
Read more →ILMNIllumina Reports Financial Results for Third Quarter of Fiscal Year 2022 Revenue of $1.12 billion for Q3 2022, up 1% from Q3 2021, and up 3% on a constant currency basis GAAP diluted loss per share of $(24.26) for Q3 2022, ...
SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN ) today announced its financial results for the third quarter of fiscal year 2022, which include consolidated financial results for GRAIL. "Our third-quarter results were in line with our expectations, with tr
Read more →ILMNIllumina Introduces New Research Test to Address One of the Most Common Infections in the United States Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new research test for genitourinary...
Genitourinary tract infections are among the most common community and healthcare-associated infections, and rising drug resistance causes increasing morbidity and mortality. This announcement comes after the October launch of two research tests enabling high-risk virus surveilla
Read more →ILMNIllumina and GenoScreen Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics company, today...
Transformative alliance will help advance the World Health Organization's strategy to end the global TB epidemic by 2035 "Through our partnership, we will enable lower-income countries to confront the pervasive threat of TB and work toward eliminating it," said Phil Febbo , chie
Read more →ILMNIllumina et GenoScreen font cause commune pour élargir l'accès au dépistage génomique de la tuberculose multirésistante Illumina Inc. (NASDAQ: ILMN), un leader mondial dans le domaine du séquençage de l'ADN et des technologies basées sur les réseaux, et GenoScreen, une ...
Cette alliance transformatrice contribuera à faire avancer la stratégie de l'Organisation mondiale de la santé visant à mettre fin à l'épidémie mondiale de tuberculose d'ici 2035. « Grâce à notre partenariat, nous permettrons aux pays à faible revenu de faire face à la menace om
Read more →ILMNIllumina to Host Second Annual Virtual ESG Investor Event on Friday, October 28, 2022 Illumina, Inc. (NASDAQ: ILMN) today announced that it will host its second annual virtual Environment, Social and Corporate Governance (ESG) focused...
SAN DIEGO , Oct. 17, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that it will host its second annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:30 am Pacific Time ( 12:30 pm Eastern Time ), Friday, October 28, 20
Read more →ILMNIllumina Launches Strategic Research Collaboration with AstraZeneca to Accelerate Drug Target Discovery Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a strategic research collaboration with ...
Aims to improve efficiency of pharma pipelines by leveraging industry-leading ability to identify genetic variants that contribute to human disease SAN DIEGO , Oct. 11, 2022 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technolo
Read more →ILMNIllumina to Announce Third Quarter 2022 Financial Results on Thursday, November 3, 2022 Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the third quarter 2022 following the close of market on Thursday,...
SAN DIEGO , Oct. 6, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) announced today that it will issue results for the third quarter 2022 following the close of market on Thursday, November 3 , 2022. On the same day, at 2:00 pm Pacific Time ( 5:00 pm Eastern Time ) Francis d
Read more →ILMNIllumina dévoile la série révolutionnaire NovaSeq X pour accélérer les découvertes génomiques et améliorer la santé humaine Illumina, Inc. (NASDAQ: ILMN), un leader mondial dans le séquençage de l'ADN et les technologies basées sur les analyses, a annoncé aujourd'hui le...
Notre séquenceur à haut débit le plus durable réduit de 90 % les emballages et de 50 % les déchets plastiques, et élimine les expéditions de glace carbonique, améliorant ainsi l'accès à la médecine génomique dans le monde entier SAN DIEGO , 30 septembre 2022 /PRNewswire/ -- Illu
Read more →ILMNRevolutionäre NovaSeq X-Serie von Illumina: Rasche Beschleunigung genomischer Entdeckungen und Verbesserung der menschlichen Gesundheit Illumina, Inc. (NASDAQ: ILMN), ein weltweit führender Anbieter von DNA-Sequenzierungs- und Array-Technologien, hat heute die Markteinführung der...
Die neue Technologie ermöglicht ein Höchstmaß an Genauigkeit in großem Maßstab und die Sequenzierung von mehr als 20.000 Genomen pro Jahr Unser nachhaltigster Hochdurchsatz-Sequenzer reduziert den Verpackungsaufwand um 90 % und den Plastikmüll um 50 % und macht den Versand von T
Read more →ILMNIllumina lança a revolucionária série NovaSeq X para acelerar as descobertas genômicas e melhorar a saúde humana A Illumina, Inc. (NASDAQ: ILMN), líder global em sequenciamento de DNA e tecnologias baseadas em array, anunciou hoje o lançamento da série NovaSeq™...
A nova tecnologia permite os mais altos níveis de precisão em imensa escala, com capacidade de sequenciar mais de 20 mil genomas por ano O sequenciador de alto rendimento mais sustentável da Ilumina oferece 90% de redução em embalagens e 50% de redução de resíduos plásticos e el
Read more →ILMNIllumina revela la revolucionaria NovaSeq X Series para acelerar rápidamente los descubrimientos genómicos y mejorar la salud humana Illumina, Inc. (NASDAQ: ILMN), líder global en secuenciación de ADN y tecnologías basadas en matrices, anunció hoy el lanzamiento de NovaSeq™ X...
La nueva tecnología permite los niveles más altos de precisión a una escala inmensa, con la capacidad de secuenciar más de 20.000 genomas al año Nuestro secuenciador de alto rendimiento más sostenible ofrece una reducción del 90 % en el empaque y una disminución del 50 % en los
Read more →ILMNIllumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of the NovaSeq™ X Series...
New technology enables highest levels of accuracy at immense scale, with the power to sequence more than 20,000 genomes per year Our most sustainable high-throughput sequencer delivers 90% reduction in packaging and 50% reduction in plastic waste, and eliminates dry ice shipment
Read more →ILMNIllumina Introduces Multiple Breakthrough Sequencing Innovations at Inaugural Genomics Forum Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced multiple breakthrough sequencing...
New sequencing technologies and capabilities will accelerate the genomic discoveries and clinical insights needed to transform human health Revolutionary NovaSeq X Series sets new benchmark for speed, scale, accuracy, and sustainability SAN DIEGO , Sept. 29, 2022 /PRNewswire/ -
Read more →ILMNIllumina presenta la revolucionaria serie NovaSeq X para acelerar los descubrimientos genómicos - Illumina presenta la revolucionaria serie NovaSeq X para acelerar los descubrimientos genómicos y mejorar la salud humana La nueva tecnología...
- Illumina presenta la revolucionaria serie NovaSeq X para acelerar los descubrimientos genómicos y mejorar la salud humana La nueva tecnología permite alcanzar los más altos niveles de precisión a una escala inmensa, con la capacidad de secuenciar más de 20.000 genomas al año
Read more →ILMNIllumina Genomics Forum Sold Out, Announces Opportunity to View Innovation Roadmap Session via Livestream Illumina, Inc. (NASDAQ: ILMN) today announced that its inaugural Illumina Genomics Forum, being held in San Diego from September 28 through October...
SAN DIEGO , Sept. 26, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that its inaugural Illumina Genomics Forum, being held in San Diego from September 28 through October 1 , is sold out. To accommodate additional interest, on Thursday, September 29 , Illumi
Read more →ILMNIllumina to Host Upcoming Investor Day Illumina, Inc. (Nasdaq: ILMN) will host its 2022 Investor Day on Monday, October 3rd starting at 8:00am Pacific Time in San Diego, CA. The event will ...
SAN DIEGO , Sept. 19, 2022 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN ) will host its 2022 Investor Day on Monday, October 3 rd starting at 8:00am Pacific Time in San Diego, CA. The event will feature presentations by members of Illumina's executive team and conclude with a Q&A
Read more →ILMNIllumina Genomics Forum to Feature Nobel Laureate Frances Arnold as part of Distinguished Panel on How the Genomics Revolution Is Transforming Patient Care Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will convene a panel titled...
Speakers will discuss how genomics drives more informed, inclusive, and proactive care SAN DIEGO , Sept. 19, 2022 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today announced that it will convene a panel titled "C
Read more →ILMNIllumina Accelerator Invests in the Fifth Global Funding Cycle of Startups Advancing Breakthrough Therapeutics, Diagnostics, Women's Health, and Sustainable Agriculture Applications Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it has invested in six genomics...
Six startups from Indonesia , Ireland , Israel , South Africa , United Kingdom and the United States will receive seed investment and access to technology and expertise SAN DIEGO , Sept. 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing a
Read more →ILMNIllumina Genomics Forum to Convene Leading Visionaries to Explore Architecting Health's Radically New Infrastructure Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will convene a panel of...
The panel will generate ideas and inspiration to build the foundational elements needed to make genomic health equitable, informed, and accountable SAN DIEGO , Sept. 12, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based techno
Read more →ILMNIllumina Announces Opportunity to View Live Webcast of Illumina Genomics Forum Innovation Roadmap Session Followed by Investor Conference Call Illumina, Inc. (NASDAQ:ILMN) today announced that investors, analysts, and other interested parties may view a live webcast of the Innovation Roadmap ...
SAN DIEGO , Sept. 8, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that investors, analysts, and other interested parties may view a live webcast of the Innovation Roadmap session of the Illumina Genomics Forum, which will be hosted by Francis deSouza, Chief
Read more →ILMNLes dernières recherches présentées lors de l'édition 2022 du congrès de l'ESMO mettent en lumière l'impact du profilage génomique complet pour les patients atteints de cancer Illumina, Inc. (NASDAQ: ILMN), un leader mondial dans le séquençage de l'ADN et les technologies basées sur les analyses, a annoncé aujourd'hui la...
Les présentations incluront des données probantes sur la façon dont les signatures génomiques et le séquençage de prochaine génération peuvent améliorer les soins aux patients atteints de cancer. SAN DIEGO , 7 septembre 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), un lea
Read more →ILMNIllumina Genomics Forum to Feature Diverse Lineup of Visionary Global Leaders Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the release of the full agenda for its ...
Full agenda now available for September 28–October 1 event SAN DIEGO , Sept. 7, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today announced the release of the full agenda for its inaugural Illumina Genomics
Read more →ILMNNeueste Forschungsergebnisse auf dem ESMO-Kongress 2022 zeigen die Bedeutung umfassender genomischer Profilerstellung für Krebspatienten Illumina, Inc. (NASDAQ: ILMN), ein weltweit führender Anbieter von DNA-Sequenzierungs- und Array-Technologien, gab heute bekannt, dass auf der...
Die Vorträge werden zeigen, wie genomische Signaturen und Sequenzierung der nächsten Generation die Versorgung von Krebspatienten verbessern können SAN DIEGO , 7. September 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), ein weltweit führender Anbieter von DNA-Sequenzierung
Read more →ILMNIllumina Intends to Appeal European Commission's Decision in GRAIL Deal Illumina, Inc. (NASDAQ:ILMN), today received a decision from the European Commission prohibiting the company's acquisition of GRAIL. The company is...
In addition, to prepare for the anticipated divestment order from the European Commission in the coming months, the company will begin reviewing strategic alternatives for GRAIL in the event the divestiture is not stayed pending Illumina's appeal. The merger of Illumina and GRAI
Read more →ILMNIllumina Intends to Appeal European Commission's Decision in GRAIL Deal
Illumina Intends to Appeal European Commission's Decision in GRAIL Deal SAN DIEGO, September 6, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), today received a decision from the European Commission prohibiting the company's acquisition of GRAIL. The company is reviewing the
Read more →ILMNCongreso ESMO 2022:Perfiles genómicos integrales para pacientes con cáncer Illumina, Inc. (NASDAQ: ILMN), líder mundial en secuenciación de ADN y tecnologías basadas en matriz, anunció hoy la próxima presentación de...
Las últimas investigaciones en el Congreso ESMO 2022 muestran el impacto de la elaboración de perfiles genómicos integrales para pacientes con cáncer Las presentaciones incluirán evidencia sobre cómo las firmas genómicas y la secuenciación de próxima generación pueden mejorar la
Read more →ILMNAdministrative Law Judge Rules in Favor of Illumina in FTC Challenge of GRAIL Deal Illumina, Inc. (NASDAQ:ILMN), today received a favorable decision from the Administrative Law Judge (ALJ) presiding over the Federal Trade...
"As we've stated from the outset, this transaction is procompetitive, will advance innovation, lower healthcare costs and save lives. We are pleased that, after considering the evidence, the ALJ has reached the same conclusion," said Charles Dadswell , General Counsel of Illumina
Read more →ILMNIllumina Deepens Commitment to Customers in China with New Manufacturing Site Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the opening of its first manufacturing ...
Investment in new Shanghai -based facility will allow the company to better serve its customers and meet growing demand SAN DIEGO , Aug. 30, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today announced the o
Read more →ILMNIllumina Genomics Forum to Feature Tennis Legend Chris Evert on the Role Genomics Played in her Cancer Fight Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature International...
Global conference to focus on advancing the life-saving impacts of genomic health care SAN DIEGO , Aug. 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today announced that it will feature International Ten
Read more →ILMNIllumina Genomics Forum to Feature 23andMe Co-founder and CEO Anne Wojcicki Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature Anne Wojcicki,...
SAN DIEGO , Aug. 22, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today announced that it will feature Anne Wojcicki , co-founder and CEO of personal genomics company 23andMe, at its inaugural Illumina Genomi
Read more →ILMNMinderoo Foundation and Illumina Commit $40M AUD to Apply Advanced Genomics to Marine Conservation Minderoo Foundation and Illumina, Inc. (NASDAQ: ILMN), today announced a 40 million Australian dollar (US $27.8 million) partnership that will...
New partnership will use the power of high-throughput sequencing to measure and understand marine life in our oceans at a rate that eclipses traditional research methods Minderoo Foundation's director of OceanOmics, Dr. Steve Burnell , said that scaling environmental DNA (eDNA)
Read more →ILMN▲ +8.8%on this newsshared move
Illumina Genomics Forum to Feature American Cancer Society CEO Karen Knudsen on the Future of Cancer Genomics Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature Dr. Karen...
Session will showcase the rapidly growing use and groundbreaking impact of clinical genomics in oncology SAN DIEGO , Aug. 15, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today announced that it will feature
Read more →ILMNIllumina Reports Financial Results for Second Quarter of Fiscal Year 2022 Revenue of $1.16 billion for Q2 2022, up 3% from Q2 2021, and up 5% on a constant currency basis GAAP diluted loss per share of $(3.40) for Q2 2022,...
SAN DIEGO , Aug. 11, 2022 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN ) today announced its financial results for the second quarter of fiscal year 2022, which include consolidated financial results for GRAIL. "Our second quarter results did not meet our expectations as challen
Read more →ILMNIllumina Genomics Forum to Feature Bill Gates and Distinguished Health Leaders Addressing Need for Global Access to Genomics Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that on September 30, its Illumina...
Speakers will outline critical steps needed to achieve health equity SAN DIEGO , Aug. 8, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today announced that on September 30 , its Illumina Genomics Forum (IGF)
Read more →ILMNIllumina Unveils its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the release of Illumina DRAGEN™ v4.0,...
DRAGEN™ v4.0 brings greater accuracy, comprehensiveness, and efficiency to genomic analysis than ever before, unlocking the full potential of genomics to improve human health SAN DIEGO , July 27, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequenc
Read more →ILMNIllumina Announces Inaugural Illumina Genomics Forum with a Conversation with Former U.S. President Barack Obama Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that former President of the United...
Global conference to focus on advancing the transformative impacts of genomic health SAN DIEGO , July 18, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today announced that former President of the United Stat
Read more →ILMNIllumina figure parmi les premières entreprises au monde à recevoir l'approbation de ses objectifs zéro émission nette sur des critères scientifiques Illumina, Inc. (NASDAQ: ILMN), leader mondial dans le domaine du séquençage de l'ADN et des technologies basées sur les réseaux, a annoncé...
La Science Based Targets initiative a validé les objectifs d'Illumina visant à atteindre zéro émission nette de gaz à effet de serre d'ici 2050 SAN DIEGO , 14 juillet 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), leader mondial dans le domaine du séquençage de l'ADN et de
Read more →ILMNIllumina Among First in the World to Receive Approval of Science-Based Net-Zero Target Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today it is among the first group of...
The Science Based Targets initiative has validated Illumina's targets to reach Net-Zero greenhouse gas emissions by 2050 SAN DIEGO , July 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, announced today it i
Read more →ILMNIllumina erhält als eines der ersten Unternehmen weltweit die Genehmigung für das wissenschaftsbasierte Netto-Null-Ziel Illumina, Inc. (NASDAQ: ILMN), ein weltweit führender Anbieter von DNA-Sequenzierung und Array-basierten Technologien, hat heute bekannt gegeben, als ...
Die Science Based Targets-Initiative hat die Ziele von Illumina bestätigt, bis 2050 Netto-Null-Treibhausgasemissionen zu erreichen SAN DIEGO , 14. Juli 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), ein weltweit führender Anbieter von DNA-Sequenzierung und Array-basierten
Read more →ILMNIllumina to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022 Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2022 following the close of market on Thursday, August ...
SAN DIEGO , July 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that it will issue results for the second quarter 2022 following the close of market on Thursday, August 11 , 2022. On the same day, at 2:00 pm Pacific Time ( 5:00 pm Eastern Time ) Francis
Read more →ILMNIllumina entre los primeros en el mundo en recibir la aprobación del Science-Based Net-Zero Target Illumina, Inc. (NASDAQ: ILMN), líder mundial en secuenciación de ADN y tecnologías basadas en matrices, anunció hoy que se encuentra entre el primer...
La iniciativa Science Based Targets ha validado los objetivos de Illumina para alcanzar las emisiones de gases de efecto invernadero Net-Zero para 2050 SAN DIEGO , 14 de julio de 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), líder mundial en secuenciación de ADN y tecnolo
Read more →ILMNIllumina investit dans un fonds de capital-risque de 30 millions de livres sterling pour faire progresser les avancées concernant la santé humaine Illumina, Inc. (NASDAQ: ILMN), un leader mondial dans le séquençage de l'ADN et les technologies basées sur des réseaux, a annoncé aujourd'hui sa...
L'investissement de LifeArc, Illumina et Illumina Ventures financera des startups dans le domaine de la génomique pour les diplômés d'Illumina Accelerator Cambridge SAN DIEGO , 30 juin 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), un leader mondial dans le séquençage de l
Read more →ILMNIllumina investiert in einen 30-Millionen-Pfund-Venture-Fonds, um bahnbrechende Entwicklungen im Bereich der menschlichen Gesundheit voranzutreiben Illumina, Inc. (NASDAQ: ILMN), ein weltweit führender Anbieter von DNA-Sequenzierungs- und Array-Technologien, gab heute seine Beteiligung an Time...
Investitionen von LifeArc, Illumina und Illumina Ventures finanzieren Genomik-Startups für Absolventen des Illumina Accelerator Cambridge SAN DIEGO , 30. Juni 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), ein weltweit führender Anbieter von DNA-Sequenzierungs- und Array-T
Read more →ILMNIllumina invierte en un fondo de riesgo de 30 millones de libras esterlinas Illumina, Inc. (NASDAQ: ILMN), líder mundial en secuenciación de ADN y tecnologías basadas en matrices, anunció hoy su participación en Time Boost...
La inversión de LifeArc, Illumina e Illumina Ventures financiará nuevas empresas de genómica para los graduados de Illumina Accelerator Cambridge SAN DIEGO , 28 de junio de 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), líder mundial en secuenciación de ADN y tecnologías b
Read more →ILMNIllumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced its participation in Time Boost...
Investment from LifeArc, Illumina, and Illumina Ventures will fund genomics startups for Illumina Accelerator Cambridge graduates SAN DIEGO , June 28, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today annou
Read more →ILMNIllumina lança teste de pesquisa desenvolvido em conjunto com a Merck para revelar dados mais profundos sobre o genoma tumoral A Illumina, Inc. (NASDAQ: ILMN), líder global em sequenciamento de DNA e tecnologias baseadas em arrays, anunciou hoje o lançamento de um teste de...
O novo ensaio traz a tecnologia HRD validada da Myriad Genetics para o Illumina TruSight™ Oncology 500, um teste pan-câncer único e abrangente para identificar as principais variantes críticas para o desenvolvimento e progressão do câncer SAN DIEGO , 22 de junho de 2022 /PRNewsw
Read more →ILMNIllumina lance un test de recherche développé en collaboration avec Merck pour mieux comprendre le génome des tumeurs Illumina, Inc. (NASDAQ: ILMN), un leader mondial du séquençage de l'ADN et des technologies basées sur les analyses, a annoncé aujourd'hui le...
La nouvelle analyse apporte la technologie HRD validée de Myriad Genetics au TruSight™ Oncology 500 d'Illumina, un test de dépistage du cancer unique et complet permettant d'identifier les variants clés essentiels au développement et à la progression du cancer « Le statut HRD es
Read more →ILMNIllumina bringt gemeinsam mit Merck entwickelten Forschungstest auf den Markt, um tiefere Einblicke in das Tumorgenom zu gewinnen Illumina, Inc. (NASDAQ: ILMN), ein weltweit führender Anbieter von DNA-Sequenzierungs- und Array-Technologien, gab heute die Markteinführung eines...
Neuer Assay nutzt validierte HRD-Technologie von Myriad Genetics in Kombination mit Illumina TruSight™ Oncology 500, einem einzigen, umfassenden Pan-Krebs-Test zur Identifizierung von Schlüsselvarianten, die für die Entstehung und das Fortschreiten von Krebs entscheidend sind SA
Read more →ILMNIllumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of a research test,...
New assay brings validated HRD technology from Myriad Genetics to the Illumina TruSight™ Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer development and progression "HRD status has emerged as an important biomarker in tumors tha
Read more →ILMNIllumina lanza una prueba de investigación desarrollada en conjunto con Merck Illumina, Inc. (NASDAQ: ILMN), líder mundial en secuenciación de ADN y tecnologías basadas en matriz, anunció hoy el lanzamiento de una prueba de...
El nuevo ensayo trae la tecnología HRD validada de Myriad Genetics a Illumina TruSight™ Oncology 500, una prueba pancancerosa única y completa para identificar variantes claves críticas para el desarrollo y la progresión del cáncer SAN DIEGO , 22 de junio de 2022 /PRNewswire/ --
Read more →ILMNJOYDEEP GOSWAMI APPOINTED INTERIM CFO; SAM SAMAD TO DEPART ILLUMINA Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami, Chief Strategy and...
SAN DIEGO , June 9, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami , Chief Strategy and Corporate Development Officer, will also serve as interim Chief Financial Officer while th
Read more →ILMNIllumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today shared key customer-focused announcements and...
SAN DIEGO , June 7, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today shared key customer-focused announcements and presentations it will make at the Advances in Genome Biology and Technology (AGBT) General
Read more →ILMN▲ +5.7%on this newsshared move
Illumina to showcase the transformational impact of comprehensive genomic profiling in unlocking precision medicine for cancer patients, at ASCO Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the acceptance of seven key oncology...
"At Illumina, we are seeing increased adoption of comprehensive genomic profiling in both in-house pathology labs and centralized labs to inform and enhance patient care," said Keegan. "Through our involvement in this year's ASCO, we look forward to learning more about and explor
Read more →ILMNIllumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion diagnostic ...
First companion diagnostic claim for Illumina's TruSight™ Oncology Comprehensive (EU) test enables targeted therapy with Bayer's VITRAKVI® (larotrectinib) for patients with NTRK fusion cancer SAN DIEGO , May 24, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leade
Read more →ILMNIllumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care Illumina, Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, and Allegheny Health Network (AHN), an integrated...
Study will evaluate whether blood-based testing can inform oncology providers about genetic variations within a patient's cancer, which may influence choice of treatment based on cancer stage and type SAN DIEGO , May 18, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) a glob
Read more →ILMN▼ -5.2%on this news· ran to -29% by day 3
Illumina and Deerfield Management partner to accelerate drug development Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Deerfield Management, a healthcare investment...
First-of-its-kind partnership will identify drug targets and accelerate novel therapy development using genomics and artificial intelligence SAN DIEGO , May 5, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, an
Read more →ILMN▼ -5.2%on this news· ran to -29% by day 3
Illumina Reports Financial Results for First Quarter of Fiscal Year 2022 Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2022, which include consolidated financial...
SAN DIEGO , May 5, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced its financial results for the first quarter of fiscal year 2022, which include consolidated financial results for GRAIL. "Illumina maintained strong momentum in the first quarter, particularly
Read more →ILMNIllumina To Webcast Upcoming Investor Conference Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: BofA Securities 2022...
SAN DIEGO , April 28, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that its executives will be speaking at the following investor conference: The live webcast can be accessed under the Investor Info section of Illumina's website under the "company" tab at
Read more →ILMNIllumina Supports Leading German Hospital to Accelerate Genetic Disease Diagnosis in Critically Ill Children Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced an agreement with Germany's Hannover...
Hannover Medical School study will evaluate the use of whole-genome sequencing to show positive impact of earlier diagnosis and treatment for children with suspected genetic disorders SAN DIEGO , April 25, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in D
Read more →ILMNIllumina apoya el diagnóstico de enfermedades genéticas en niños gravemente enfermos Illumina, Inc. (NASDAQ: ILMN), un líder mundial en tecnologías de secuenciación del ADN y basadas en conjuntos, ha anunciado hoy un acuerdo con la...
-Illumina apoya al principal hospital alemán para acelerar el diagnóstico de enfermedades genéticas en niños gravemente enfermos Un estudio de la Facultad de Medicina de Hannover evaluará el uso de la secuenciación del genoma completo para demostrar el impacto positivo de un dia
Read more →ILMNIllumina unterstützt führendes deutsches Krankenhaus bei der Beschleunigung der Diagnose von genetischen Krankheiten bei schwerkranken Kindern Illumina, Inc. (NASDAQ: ILMN), ein weltweit führendes Unternehmen für DNA-Sequenzierung und Array-basierte Technologien, hat heute eine Vereinbarung...
Eine Studie der Medizinischen Hochschule Hannover wird die Verwendung der Gesamtgenomsequenzierung bewerten, um die positiven Auswirkungen einer früheren Diagnose und Behandlung bei Kindern mit Verdacht auf genetische Störungen aufzuzeigen SAN DIEGO , 25. April 2022 /PRNewswire/
Read more →ILMNIllumina apporte son soutien à un grand hôpital allemand pour accélérer le diagnostic des maladies génétiques chez les enfants gravement malades Illumina, Inc. (NASDAQ: ILMN), un leader mondial dans le domaine du séquençage de l'ADN et des technologies basées sur les réseaux, a annoncé...
Une étude de la Hannover Medical School évaluera l'utilisation du séquençage du génome entier pour montrer l'impact positif d'un diagnostic et d'un traitement précoces pour les enfants atteints de troubles génétiques présumés SAN DIEGO , 25 avril 2022 /PRNewswire/ -- Illumina, I
Read more →ILMNIllumina to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022 Illumina, Inc. (NASDAQ: ILMN) today announced that it will issue results for the first quarter 2022 following the close of market on Thursday, May 5, ...
SAN DIEGO , April 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that it will issue results for the first quarter 2022 following the close of market on Thursday, May 5 , 2022. On the same day, at 2:00 pm Pacific Time ( 5:00 pm Eastern Time ) Francis deSo
Read more →ILMNIllumina amplia o acesso à genômica na América Latina por meio de um novo e avançado Centro de Soluções A Illumina, Inc. (NASDAQ: ILMN), líder global em sequenciamento de DNA e tecnologias baseadas em array, anunciou hoje a inauguração do seu novo e...
O Centro de Soluções regional em São Paulo, Brasil, permitirá que os clientes tenham acesso ao treinamento em sequenciamento e à expertise de última geração para melhorar os resultados para os pacientes SAN DIEGO , 13 de abril de 2022 /PRNewswire/ -- A Illumina, Inc. (NASDAQ: IL
Read more →ILMNIllumina amplía el acceso a la genómica en Latinoamérica a través de un nuevo centro de soluciones de última generación Illumina, Inc. (NASDAQ: ILMN), líder global en secuenciación de ADN y tecnologías basadas en matrices, anunció hoy el lanzamiento de su nuevo centro...
El centro regional de soluciones en São Paulo, Brasil, permitirá a los clientes acceder a capacitación y conocimientos en secuenciación de última generación para mejorar los resultados de los pacientes SAN DIEGO , 13 de abril de 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN
Read more →ILMNIllumina Expands Access to Genomics in Latin America through New State-of-the-Art Solution Center Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of its new state-of-the-art ...
Regional Solution Center in São Paulo, Brazil will enable customer access to next-generation sequencing training and expertise to improve patient outcomes SAN DIEGO , April 12, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based
Read more →ILMNJohn Frank Joins Illumina as Chief Public Affairs Officer Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of John Frank as the...
SAN DIEGO , April 11, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, announced today the appointment of John Frank as the Company's Chief Public Affairs Officer (CPAO). Frank joins Illumina on April 18 from Mic
Read more →ILMNIllumina Releases Annual Corporate Social Responsibility Report Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today released its annual Corporate Social...
Report highlights contributions of genomics to advances in public health and overall health of our planet SAN DIEGO , April 7, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), a global leader in DNA sequencing and array-based technologies, today released its annual Corporate
Read more →ILMNIllumina dévoile un test révolutionnaire de profilage génomique complet pour le cancer en Europe Illumina, Inc. (NASDAQ:ILMN) a annoncé aujourd'hui le lancement de TruSight™ Oncology (TSO) Comprehensive (EU), un test unique qui évalue plusieurs...
Ce nouveau kit de diagnostic in vitro (DIV) par profilage génomique complet (CGP) couvre un large éventail de mutations et de biomarqueurs actuels et émergents associés aux directives de la Société européenne d'oncologie médicale, aux étiquettes des médicaments et aux essais clin
Read more →ILMNIllumina stellt bahnbrechenden Test für umfassendes genomisches Profiling bei Krebs in Europa vor Illumina, Inc. (NASDAQ:ILMN) hat heute die Markteinführung von TruSight™ Oncology (TSO) Comprehensive (EU) bekannt gegeben, einem Test, der...
Der Einzel-In-vitro-Diagnostik-Test hilft, Entscheidungen zur Therapie gemäß klinischer Richtlinien zu treffen, um so früh wie möglich im Krankheitsverlauf Präzisionsmedizin anzuwenden SAN DIEGO , 16. März 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) hat heute die Marktei
Read more →ILMNSpoločnosť Illumina predstavila prelomový komplexný test genomického profilovania rakoviny v Európe Spoločnosť Illumina, Inc. (NASDAQ:ILMN) dnes oznámila uvedenie komplexného testu TruSight™ Oncology (TSO) Comprehensive (EÚ), ktorý hodnotí viacero...
Jediný diagnostický test in vitro pomáha pri rozhodovaní o liečbe v súlade s klinickými usmerneniami, aby sa umožnila presná medicína v skoršom štádiu ochorenia. SAN DIEGO , 16. marca 2022 /PRNewswire/ -- Spoločnosť Illumina, Inc. (NASDAQ: ILMN ) dnes oznámila uvedenie komplexné
Read more →ILMNIllumina svela un innovativo test completo per la profilazione genomica del tumore in Europa Illumina, Inc. (NASDAQ:ILMN) ha annunciato oggi il lancio di TruSight™ Oncology (TSO) Comprehensive (EU), un singolo test che valuta più geni...
Questo nuovo kit completo di profilazione genomica (CGP) per la diagnostica in vitro (IVD) copre una vasta gamma di mutazioni e biomarcatori attuali ed emergenti associati alle linee guida della European Society for Medical Oncology, alle etichette dei farmaci e agli studi clinic
Read more →ILMNSpolečnost Illumina představila v Evropě přelomový komplexní test pro genomové profilování Společnost Illumina, Inc. (NASDAQ: ILMN) v úterý oznámila uvedení testu TruSight™ Oncology (TSO) Comprehensive (EU), který hodnotí více nádorových...
Jednotný diagnostický test in vitro pomáhá informovat rozhodování o léčbě dle klinických pokynů a umožňuje tak precizní medicínské zásahy v dřívějších fázích onemocnění SAN DIEGO , 16. března 2022 /PRNewswire/ -- Společnost Illumina, Inc. (NASDAQ: ILMN ) v úterý oznámila uvedení
Read more →ILMNIllumina Accelerator Invests in Seven Omics Startups Advancing Breakthrough Therapeutics, Diagnostics, DNA Storage, Mental Wellness, and Sustainable Foods Applications Illumina, Inc. (NASDAQ: ILMN) has invested in seven new genomics companies to join the fourth global funding cycle of Illumina Accelerator San...
Illumina Accelerator portfolio grows to 68 startups 93% of graduate companies successfully secured additional capital SAN DIEGO , March 16, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) has invested in seven new genomics companies to join the fourth global funding cycle o
Read more →ILMNIllumina prezentuje w Europie przełomowy kompleksowy test profilowania genomowego pod kątem nowotworów Spółka Illumina, Inc. (NASDAQ:ILMN) poinformowała dzisiaj o wprowadzeniu TruSight™ Oncology (TSO) Comprehensive (EU), pojedynczego testu...
Pojedynczy test diagnostyczny in vitro zwiększający możliwości podejmowania decyzji terapeutycznych zgodnie z wytycznymi klinicznymi, umożliwiający jednocześnie stosowanie precyzyjnego leczenia na wczesnym etapie choroby. SAN DIEGO , 15 marca 2022 r. /PRNewswire/ -- Spółka Illum
Read more →ILMNIllumina presenta en Europa una innovadora prueba integral de perfilado genómico para el cáncer Illumina, Inc. (NASDAQ:ILMN) anunció hoy el lanzamiento de TruSight™ Oncology (TSO) Comprehensive (EU), una prueba única que evalúa múltiples genes...
Este nuevo kit completo de perfil genómico (CGP) para diagnóstico in vitro (IVD) cubre una amplia gama de mutaciones y biomarcadores actuales y emergentes asociados con las directrices, las etiquetas de medicamentos y los ensayos clínicos de la Sociedad Europea de Oncología Médic
Read more →ILMNIllumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe Illumina, Inc. (NASDAQ:ILMN) today announced the launch of TruSight™ Oncology (TSO) Comprehensive (EU), a single test that assesses multiple tumor...
This new in vitro diagnostic (IVD) comprehensive genomic profiling (CGP) kit covers a broad range of mutations and current and emerging biomarkers associated with the European Society for Medical Oncology guidelines, drug labels and clinical trials, maximizing the chances of find
Read more →ILMNIllumina Welcomes Carissa Rollins as Chief Information Officer Illumina, Inc. (NASDAQ: ILMN) announced today that Carissa Rollins will join the company as Chief Information Officer on March 14, 2022. Rollins...
SAN DIEGO , March 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) announced today that Carissa Rollins will join the company as Chief Information Officer on March 14, 2022 . Rollins brings over 30 years of business technology transformation and digital and consumerization
Read more →ILMNIllumina To Webcast Upcoming Investor Conference Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Cowen Health Care Conference ...
SAN DIEGO , Feb. 21, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that its executives will be speaking at the following investor conference: The live webcast can be accessed under the Investor Info section of Illumina's website under the "company" tab at w
Read more →ILMNIllumina Reports Financial Results for Fourth Quarter and Fiscal Year 2021 Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2021, which include the consolidated...
SAN DIEGO , Feb. 10, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced its financial results for the fourth quarter and fiscal year 2021, which include the consolidated financial results of GRAIL. Fourth quarter consolidated results: "We are seeing strength ac
Read more →ILMNIllumina To Webcast Upcoming Investor Conferences Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: SVB Leerink 2022 Global...
SAN DIEGO , Feb. 3, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that its executives will be speaking at the following investor conferences: The live webcasts can be accessed under the Investor Info section of the "company" tab at www.illumina.com . A repl
Read more →ILMNIllumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer Illumina, Inc. (NASDAQ:ILMN), today announced an agreement with the Jean Perrin Center at the Clermont-Ferrand University Hospital in France to...
The Jean Perrin Center, with participation from the Toulouse Oncopole and the Bordeaux University Hospital Center, will analyze biopsy samples from patients with advanced colorectal, breast, melanoma or lung cancer using CGP enabled by Illumina's TruSight™ Oncology 500 assay. "P
Read more →ILMNIllumina collaborates with National Cancer Center Japan to address a leading cause of death in Asia Illumina, Inc. (NASDAQ: ILMN) and the National Cancer Center Japan have announced an international joint research project that will use Illumina's...
SAN DIEGO , Jan. 24, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) and the National Cancer Center Japan have announced an international joint research project that will use Illumina's high-throughput DNA sequencing to analyse the blood-based genomic profile and clinical inf
Read more →ILMNIllumina to Announce Fourth Quarter & Full Year 2021 Financial Results on Thursday, February 10, 2022 Illumina, Inc. (NASDAQ: ILMN) today announced that it will issue results for the fourth quarter and full year 2021 following the close of market on...
SAN DIEGO , Jan. 20, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that it will issue results for the fourth quarter and full year 2021 following the close of market on Thursday, February 10 , 2022. On the same day, at 2:00 pm Pacific Time ( 5:00 pm Eastern
Read more →ILMN▲ +17%on this news
transcript2022 C O R P O R A T E P A R T I C I P A N T S Francis A. deSouza Illumina, Inc. - CEO & Director Robert P. Ragusa GRAIL, Inc. - CEO C O N F E R E N C E C A L L P A R T I C I P A N T S Tycho W. Peterson JPMorga
C O R P O R A T E P A R T I C I P A N T S Francis A. deSouza Illumina, Inc. - CEO & Director Robert P. Ragusa GRAIL, Inc. - CEO C O N F E R E N C E C A L L P A R T I C I P A N T S Tycho W. Peterson JPMorgan Chase & Co, Research Division - Senior Analyst Joshua J. Ofman GRAIL, Inc
Read more →ILMNIllumina collaborates with Nashville Biosciences to accelerate medicines development Illumina, Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC), today...
SAN DIEGO , Jan. 10, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) and Nashville Biosciences, LLC, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced a multi-year agreement to accelerate medicines development through large-scale genomi
Read more →ILMNIllumina Partners with Agendia to Expand Genomic Testing in Breast Cancer Care Illumina, Inc. (NASDAQ: ILMN) today announced a multi-year partnership with Agendia N.V., a world leader in precision oncology for breast cancer, to...
Illumina and Agendia plan to develop new tests to enhance the care and management of breast cancer patients, utilizing the Illumina MiSeq™Dx sequencing platform to expand the range of gene panels available for solid tumor analysis. We expect Agendia's flagship test, MammaPrint™,
Read more →ILMNIllumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in...
The partnership spans current and future CDx programs, with plans to add CDx claims to an in vitro diagnostic test Illumina is developing that is based on the content of TruSight™ Oncology 500 (TSO 500). The first program will co-develop a CDx for a Boehringer Ingelheim investiga
Read more →ILMNIllumina delivers 2021 results ahead of expectations, strong 2022 guidance and deep pipeline of long-term growth opportunities at 2022 J.P. Morgan Healthcare Conference Illumina, Inc. (NASDAQ:ILMN) Chief Executive Officer, Francis deSouza, discussed today the company's strong growth trajectory, including 2021 results ...
SAN DIEGO , Jan. 10, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) Chief Executive Officer, Francis deSouza, discussed today the company's strong growth trajectory, including 2021 results and 2022 guidance. deSouza also announced new partnerships and technologies that will
Read more →ILMNIllumina Enters Co-Development Partnership with SomaLogic Illumina, Inc. (NASDAQ: ILMN) today announced it has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan®...
SAN DIEGO , Jan. 5, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced it has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan® Proteomics Assay onto Illumina's current and future high throughput next-generation sequencing (
Read more →ILMNIllumina To Webcast Upcoming Investor Conference Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: J.P. Morgan Annual...
SAN DIEGO , Dec. 23, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that its executives will be speaking at the following investor conference: The live webcast can be accessed under the Investor Info section of the "company" tab at www.illumina.com . A repla
Read more →ILMNIllumina Supports Norway's Pioneering Precision Medicine Study Illumina, Inc. (NASDAQ:ILMN), today announced that it is supporting a national precision medicine study in Norway to assess the efficacy of...
Within IMPRESS-Norway, Illumina is supporting a sub-study of 500 patients comparing solid tissue biopsies with easier-to-obtain blood samples to see if regular blood testing can provide additional information on the genetic changes within a patient's cancer which may be relevant
Read more →ILMNIllumina and Sequoia Capital China Select First Startups to join Genomics Incubator in China Illumina, Inc. (NASDAQ: ILMN), and Sequoia Capital China, a leading investment firm, today jointly announced the selection of the first two startup...
SAN DIEGO , Nov. 17, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ), and Sequoia Capital China, a leading investment firm, today jointly announced the selection of the first two startup companies joining the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Po
Read more →ILMNIllumina and Genetic Alliance Launch $120 Million Global Initiative to Increase Equity and Improve Outcomes for Families Impacted by Genetic Disease Illumina, Inc. (NASDAQ: ILMN) and Genetic Alliance today announced the creation of the iHope™ Genetic Health program aimed at providing whole-genome...
SAN DIEGO , Nov. 16, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) and Genetic Alliance today announced the creation of the iHope ™ Genetic Health program aimed at providing whole-genome sequencing access (WGS) to tens of thousands of patients across the globe impacted by g
Read more →ILMNIllumina Reports Financial Results for Third Quarter of Fiscal Year 2021 Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the third quarter of fiscal year 2021, which include the consolidated...
SAN DIEGO , Nov. 4, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced its financial results for the third quarter of fiscal year 2021, which include the consolidated financial results of GRAIL. Third quarter consolidated results: "Illumina's financial results
Read more →ILMNIllumina Supports Canada's Nationwide COVID-19 Genome Sequencing Initiative Illumina Inc. (NASDAQ: ILMN) today announced that its world-class sequencing and bioinformatics solutions are being used by HostSeq, part of the...
SAN DIEGO , Nov. 3, 2021 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN ) today announced that its world-class sequencing and bioinformatics solutions are being used by HostSeq , part of the Canadian COVID-19 Genomics Network (CanCOGeN), to identify biomarkers that can help predict
Read more →ILMNIllumina Supports Israel's National Program to Accelerate Diagnoses of Critically-Ill Newborns with Suspected Genetic Disease Illumina, Inc. (NASDAQ: ILMN) today announced an agreement with Israel's Ministry of Health (MoH) for a pilot program to implement the use of...
SAN DIEGO , Oct. 27, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced an agreement with Israel's Ministry of Health (MoH) for a pilot program to implement the use of whole-genome sequencing (WGS) in critically-ill infants suspected of having a genetic disorder
Read more →ILMNIllumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021 Illumina, Inc. (NASDAQ:ILMN) today announced that it will host its first Environment, Social and Corporate Governance (ESG) focused investor event at ...
SAN DIEGO , Oct. 20, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that it will host its first Environment, Social and Corporate Governance (ESG) focused investor event at 11:00 am Pacific Time ( 2:00 pm Eastern Time ), Tuesday, November 16, 2021 . Francis
Read more →ILMNIllumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL Ragusa succeeds Hans Bishop, who will continue to serve as Advisor to the CEO through end of 2021
Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL Ragusa succeeds Hans Bishop, who will continue to serve as Advisor to the CEO through end of 2021 SAN DIEGO, Oct. 14, 2021 / PRNewswire / -- Illumina, Inc. (NASDAQ:ILMN) today announced that Bob Ragusa has b
Read more →ILMNIllumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL Illumina, Inc. (NASDAQ:ILMN) today announced that Bob Ragusa has been appointed as Chief Executive Officer of GRAIL, a healthcare company whose...
SAN DIEGO , Oct. 14, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that Bob Ragusa has been appointed as Chief Executive Officer of GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, effective immediately. GRAIL currently o
Read more →ILMNIllumina to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021 Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the third quarter 2021 following the close of market on Thursday,...
SAN DIEGO , Oct. 13, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that it will issue results for the third quarter 2021 following the close of market on Thursday, November 4 , 2021. On the same day, at 2:00 pm Pacific Time ( 5:00 pm Eastern Time ) Francis
Read more →ILMNIllumina amplía su presencia en Latinoamérica Illumina, Inc. (NASDAQ: ILMN) anunció la creación de Illumina Colombia S.A.S. e Illumina México Productos de Biotecnología, lo que marca su...
SAN DIEGO , 30 de septiembre de 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) anunció la creación de Illumina Colombia S.A.S. e Illumina México Productos de Biotecnología, lo que marca su compromiso de expandir la genómica en Latinoamérica y aumentar el nivel de apoyo a los
Read more →ILMNIllumina Expands Presence in Latin America Illumina, Inc. (NASDAQ: ILMN) announced the creation of Illumina Colombia S.A.S. and Illumina México Productos de Biotecnología marking our...
SAN DIEGO , Sept. 30, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) announced the creation of Illumina Colombia S.A.S. and Illumina México Productos de Biotecnología marking our commitment to expand genomics in Latin America and increase the level of support for our local c
Read more →ILMNRandomized trial demonstrates whole-genome sequencing leads to precision care for critically ill infants Illumina, Inc. (NASDAQ: ILMN) scientists, together with investigators from five children's hospital across the US, have co-authored a study published ...
SAN DIEGO , Sept. 27, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) scientists, together with investigators from five children's hospital across the US, have co-authored a study published today in JAMA Pediatrics reporting findings from the NICUSeq Randomized Time-Delayed T
Read more →ILMNIllumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle Illumina, Inc. (NASDAQ: ILMN) has selected seven new genomics companies to join the third global funding cycle of Illumina Accelerator. The global...
SAN DIEGO , Sept. 15, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) has selected seven new genomics companies to join the third global funding cycle of Illumina Accelerator . The global company creation engine, focused on partnering with entrepreneurs to build breakthrough
Read more →ILMNIllumina Commits to Net Zero Global Greenhouse Gas Emissions by 2050 Illumina, Inc. (NASDAQ: ILMN) elevates climate action goals with commitments for net zero greenhouse gas emissions aligned with the Paris Agreement,...
SAN DIEGO , Sept. 9, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) elevates climate action goals with commitments for net zero greenhouse gas emissions aligned with the Paris Agreement, commits to verified Science Based Targets , signs the Business Ambition for 1.5 degree a
Read more →ILMNIllumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations Illumina, Inc. (NASDAQ: ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and...
This strategic partnership builds on an initial study conducted with Merck and leverages Illumina's relationship with Myriad Genetics (NASDAQ: MYGN ) to expand international access to the proprietary technology in Myriad's FDA approved myChoice® CDx companion diagnostic test. Ill
Read more →ILMNIllumina To Webcast Upcoming Investor Conference Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Morgan Stanley 19th Annual...
SAN DIEGO , Aug. 30, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that its executives will be speaking at the following investor conference: The live webcast can be accessed under the Investor Info section of the "company" tab at www.illumina.com . A repla
Read more →ILMNIllumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test GRAIL will remain a separate and independent unit, pending ongoing regulatory and legal review
Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test GRAIL will remain a separate and independent unit, pending ongoing regulatory and legal review SAN DIEGO, /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it
Read more →ILMNIllumina Reports Financial Results for Second Quarter of Fiscal Year 2021 Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2021. Second quarter results reflect record ...
SAN DIEGO , Aug. 5, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced its financial results for the second quarter of fiscal year 2021. Second quarter results reflect record revenue: "Illumina's record second quarter revenue exceeded expectations across all re
Read more →ILMNIllumina Donates $1 Million in Sequencing Capabilities to Mumbai to Support Sequencing-Based COVID-19 Surveillance in India Illumina, Inc. (NASDAQ: ILMN) has donated $1 million in sequencing capabilities to the Molecular Diagnostic Reference Laboratory at Kasturba...
SAN DIEGO , Aug. 3, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) has donated $1 million in sequencing capabilities to the Molecular Diagnostic Reference Laboratory at Kasturba Hospital, in the Municipal Corporate of Greater Mumbai , to help expand SARS-CoV-2 sequencing cap
Read more →ILMNIllumina Announces Board Changes Jay Flatley to step down from the Board; John W. Thompson to be appointed new Chair
Illumina Announces Board Changes Flatley to step down from the Board; John W. Thompson to be appointed new Chair SAN DIEGO March 18, 2021 Illumina, Inc. (NASDAQ: ILMN) (the Company ) today announced that Jay Flatley has decided to step down from the Board of Directors and John
Read more →ILMNGRAIL AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018 GRAIL, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page AUDITED CONSOLIDATED FINANCIAL STATEMENTS: Report of Independent
GRAIL AUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page AUDITED CONSOLIDATED FINANCIAL STATEMENTS: Report of Independent Registered Public Accounting Firm 2 Consolidated Balance Sh
Read more →ILMNDocument The following is a transcript of a webcast presented by Illumina, Inc. (the "Company") at the JPMorgan Healthcare Conference (Virtual) on
The following is a transcript of a webcast presented by Illumina, Inc. (the "Company") at the JPMorgan Healthcare Conference (Virtual) on January 11, 2021. C O R P O R A T E P A R T I C I P A N T S Alexander Aravanis Illumina, Inc. - Senior VP CTO Francis A. deSouza Illumina,
Read more →ILMNllumina to Acquire GRAIL to Launch New Era of Cancer Detection Accelerates Commercialization and Adoption of Transformative Multi-Cancer Screening Test with Potential to Detect More Cancers Earlier and Enable Better Outc
llumina to Acquire GRAIL to Launch New Era of Cancer Detection Accelerates Commercialization and Adoption of Transformative Multi-Cancer Screening Test with Potential to Detect More Cancers Earlier and Enable Better Outcomes Adds Multi-Disciplinary Team and Capabilities Harness
Read more →ILMNDocument Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina's Board of Directors
Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina's Board of Directors SAN DIEGO, CA -February 6, 2020 -- Illumina, Inc. (NASDAQ ILMN) announced today that Scott Gottlieb, M.D. has joined the company's Board of Directors, effective February 4, 2020. Dr. Gottlieb is
Read more →ILMNIllumina and Pacific Biosciences Announce Termination of Merger Agreement
Illumina and Pacific Biosciences Announce Termination of Merger Agreement SAN DIEGO & MENLO PARK, Calif.- January 2, 2020 - Illumina, Inc. (NASDAQ: ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their m
Read more →ILMNIllumina Celebrates Grand Opening of Its Solutions Center in the University of Maryland BioPark Illumina, Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems, celebrated today the grand opening of...
BALTIMORE , Oct. 29, 2019 /PRNewswire/ -- Illumina, Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems, celebrated today the grand opening of its new training facility in the University of Maryland (UM) BioPark. The 13,000-square-f
Read more →ILMNIllumina Reports Preliminary Revenue for Second Quarter of Fiscal Year 2019
Investors: Jacquie Ross, CFA 858-882-2172 ir@illumina.com Media: Eric Endicott 858-882-6822 pr@illumina.com Illumina Reports Preliminary Revenue for Second Quarter of Fiscal Year 2019 Revises 2019 Full Year Revenue Guidance San Diego -- (BUSINESS WIR
Read more →ILMNIllumina Names Susan E.
Illumina Names Susan E. Siegel to its Board of Directors Adding Decades of Leadership Experience in Personalized Medicine, Digital Health and Life Sciences SAN DIEGO--Illumina, Inc. (NASDAQ: ILMN) announced today that Sue Siegel has joined the company's Board of Directors effec
Read more →Competitive Position
How ILMN ranks across every disease it competes inCompetitive Position is a premium feature
See how ILMN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial